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ABSTRACT 
Prostate cancer is a leading cause of mortality worldwide. Patients with locally advanced 
disease have a higher risk of relapse after treatment with curative intent. Examples of risk 
factors are seminal vesicle invasion (SVI) and lymph node metastases. However, not all 
patients with adverse pathology experience recurrence. It is not fully understood how 
histopathological features are associated with progressive capacity and how to best identify 
them before treatment. The aim of this thesis was to evaluate histopathological and genetic 
prognostic factors of locally advanced prostate cancer and to correlate findings in 
preoperative biopsy with radical prostatectomy (RP) specimens.  
In Study I we evaluated 1050 RP specimens. SVI was found in 60 cases, which were further 
analyzed regarding pathological factors such as route of invasion, tumor area and Gleason 
score of the cancer component invading the seminal vesicles. We confirmed that patients with 
SVI have a higher risk of biochemical recurrence. The prognosis was poorer if cancer 
invaded the mucosa of the seminal vesicle compared to when cancer invasion was restricted 
to the muscular wall.  
The aim of Study II was to evaluate 45 morphologically distinct tissue areas in a RP 
specimen with lymph node metastases in order to identify the clone that gave rise to the 
metastases. We analyzed break-point regions, which marks a start of an amplification or a 
deletion event, to construct a phylogenetic tree showing the somatic relationship between 
samples. The greatest similarity with metastases was seen in three samples with intraductal 
carcinoma. This lesion has previously been associated with poor prognosis, although this 
study was the first to indicate a metastatic potential.  
In Study III we analyzed the prognosis of patients with SVI compared to patients with 
extraprostatic extension alone (stage categories pT3b and pT3a, respectively). Data from 
4063 pT3a cases and 1371 pT3b cases were retrieved from the National Prostate Cancer 
Register. We found that patients with stage category pT3b had a higher risk of death from 
prostate cancer and were more likely to receive postoperative treatment with androgen 
deprivation therapy or radiotherapy. They also had a greater tumor burden as measured by 
tumor length and number of positive cores and a higher Gleason score.  
In Study IV we evaluated several tumor foci and biopsy cores from 11 patients. The samples 
were sequenced and somatic profiles of the tumor foci compared with those of the biopsies. 
We found a high degree of genomic heterogeneity between foci within the same prostate. In 
eight patients the biopsies represented at least one of the tumor foci of the RP specimen. In 
only one case two somatically distinct tumors were identified in the biopsies.  
In conclusion, these studies show that prostate cancer is a morphologically and genetically 
heterogeneous disease. The poor representation of somatically different tumors in core 
biopsies suggests a diagnostic challenge as we move towards more individualized treatment. 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Prostatacancer är den vanligaste cancertypen i Sverige med ca 10 000 nya fall varje år. 
Lokaliserad prostatacancer kan botas antingen genom strålbehandling eller kirurgi. När 
prostatacancer växer utanför prostatakapseln eller det finns spridning till lokala lymfkörtlar 
säger man att tumören är lokalt avancerad. Dessa tumörer är svårare att behandla och det 
finns en högre risk för att sjukdomen kommer tillbaka efter försök till bot. Exakt vilka 
egenskaper hos tumören som gör att den kan sprida sig utanför prostatan är inte känt. Detta är 
viktigt att kartlägga då det kan förändra hur vi behandlar dessa tumörer.  
Sädesblåsorna består av två avlånga körtlar som ligger vid bakre övre hörnet av prostatan. 
När cancer invaderar sädesblåsan vilket även kallas för vesikelinvasion, är prognosen sämre 
för patienten. Sådan typ av tumörväxt kan vara svårt att diagnostisera före behandling och det 
är oftast först när patologen tittar på den bortopererade prostatan i mikroskop som man säkert 
kan ställa diagnos. Det har dock visat sig att vissa patienter med vesikelinvasion har god 
prognos. I Studie I och III i denna avhandling utvärderades prognosen för patienter med 
vesikelinvasion. I Studie I analyserade vi totalt 1050 bortopererade prostator i mikroskop, 
varav 60 hade vesikelinvasion. Dessa fall utvärderades med avseende på ett antal olika 
faktorer såsom spridningssätt, tumörarea, tumörgrad och lateralitet. Vi kom fram till att i de 
fall då tumören växte in i slemhinnan hade patienterna en högre risk för återfall. Detta har 
aldrig tidigare rapporterats. Patienterna som endast hade tumörinvasion i muskelväggen av 
sädesblåsan hade en lika god prognos som patienter utan vesikelinvasion. I studie III använde 
vi registerdata och analyserade 1371 fall av vesikelinvasion och 4063 fall av 
tumörgenombrott av prostatakapseln som inte involverade sädesblåsan. Vi fann att patienter 
med vesikelinvasion har en sämre prognos jämfört med patienter som har tumörgenombrott 
av prostatakapseln utan vesikelinvasion. De hade en högre risk att få tilläggsbehandling efter 
operation (hormoner och strålbehandling) och även en högre risk att dö av prostatacancer. 
Vidare undersökte vi de diagnostiska biopsierna som tagits före operationen och såg att 
patienter med vesikelinvasion hade en högre tumörbörda i biopsierna med avseende på 
tumörlängd, antal biopsier med tumör och grad.  
I Studie II undersökte vi ett fall där prostatacancern spridit sig till regionala lymfkörtlar i 
bäckenet. Vi mikrodissekerade 45 morfologiskt olika områden i prostatan i ett 
laserdissektionsmikroskop. Vi undersökte DNA-förändringar i de olika områdena och 
jämförde med de förändringar som fanns i metastaserna. Tre områden visade stor somatisk 
likhet med metastaserna och det visade sig att alla dessa hade samma morfologi - intraduktal 
cancer. Denna typ har tidigare associerats med dålig prognos men man vet inte riktigt varför. 
Denna studie var först med att visa att de somatiska förändringarna som finns i intraduktal 
cancer även finns i metastaserna vilket inger misstanke om att intraduktal cancer har potential 
att metastasera. Därför är det särskilt viktigt att rapportera fynd av intraduktal cancer om man 
hittar det i diagnostiska biopsier.  
I Studie IV undersöktes 11 fall av multifokal prostatacancer samt tillhörande diagnostiska 
biopsier. Syftet var att undersöka hur väl biopsierna representerar de olika tumörområdena 
  
som finns inom en prostata ur ett genetiskt perspektiv. Detta har betydelse då vi i framtiden 
sannolikt kommer att behandla tumörer olika beroende på vilka somatiska förändringar 
tumören bär på. I endast ett av fallen hittade vi somatiska förändringar i biopsierna som 
stämde överens med förändringarna inom de två stora tumörområden vi fann i prostatan. 
Denna studie tyder på att diagnostiska biopsier ger en otillräcklig bild av de genetiskt 
heterogena tumörerna som kan finnas inom en och samma prostata. Vidare kom vi fram till 
att det är en stor heterogenitet i genetik mellan olika tumörområden inom samma prostata. 
Detta innebär utmaningar i den kliniska vardagen då man framöver hoppas kunna förbättra 
behandlingen baserat på genetisk analys av tumörvävnad före operation.  
Sammanfattningsvis visar dessa studier att prostatacancer är mikroskopiskt och genetiskt en 
mycket heterogen sjukdom. Idag känner vi till flera olika riskfaktorer som innebär en högre 
risk för återfall i sjukdom för patienten. Studierna i denna avhandling har dels bekräftat 
tidigare riskfaktorer, dels påvisat nya riskfaktorer, såsom slemhinneinvasion i sädesblåsan. 
Vidare har vi för första gången visat ett samband mellan intraduktal cancer och 
metastaserande potential. Den genetiskt heterogena naturen i prostatacancer leder till 
utmaningar i diagnostiken och vi ser att representationen av dessa olika tumörer är låg i de 
diagnostiska biopsierna. Detta innebär utmaningar ur ett kliniskt perspektiv där vi går mot ett 
alltmer individanpassat behandlingsupplägg.  
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY  
Prostate cancer is a leading cause of morbidity and mortality worldwide and the second most 
common cancer among men (1). In Sweden, it is the most common non-cutaneous 
malignancy where it accounts for approximately one third of all cancers (2). The incidence of 
prostate cancer has increased rapidly during the last decades as a result of serum prostate-
specific antigen (s-PSA) testing and increased life expectancy (3). In 2016, 10 473 men were 
diagnosed with prostate cancer and 2 347 men died of the disease in Sweden (2). It becomes 
increasingly common with higher age. In 2016, the median age at diagnosis was 70 years, 
however, 151 men were younger than 50. Globally, almost 1.3 million new cases and over 
350 000 prostate cancer associated deaths were estimated in 2018, ranking as the fifth leading 
cause of cancer death in men (1). The incidence rate is high in Australia/New Zealand, 
Northern and Western Europe and North America (Figure 1). The varying incidence of 
prostate cancer between regions is partly explained by differences in diagnostic opportunities, 
including both s-PSA testing and core biopsies. However, the incidence is highest among 
men of African descent in the United States and the Caribbean, which reflects a genetic 
predisposition (4). In contrast, prostate cancer is less common in Asia. Studies have shown 
that the incidence increases in men who migrate from low to high incidence areas (5, 6). For 
example, Japanese men who migrate to the United States have a higher risk of being 
diagnosed with prostate cancer compared to men who remain in Japan (5).  
One of the unique features of prostate cancer is that many men live with latent, clinically 
undetectable tumors. In autopsy studies histologic prostate cancer is usually found in 20-30% 
of cases (7, 8). In a classic study by Sakr et al, latent prostate cancer was found in 64% of 
men aged 60 to 69 years (8). In a Hungarian study, prostate cancer was seen in 38.8% of 139 
autopsy cases between 18 and 95 years (9). However, in the age group 81 to 95, the 
prevalence was as high as 86.6%. Haas et al examined 164 autopsy cases and found prostate 
cancer in 29% but only 42.6% were considered clinically significant (7). As indicated by 
these autopsy studies, many men have indolent, clinically undetected tumors. Thus, one of 
the great challenges in the care of prostate cancer is to distinguish patients with aggressive 
disease who need early curative treatment from those with indolent tumors that can be 
monitored.  
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Figure 1. The incidence rate of prostate cancer worldwide in 2018. The incidence is high In Western 
countries. Reprinted with permission from http://gco.iarc.fr/today 
 
1.2 RISK FACTORS 
Although the etiology of prostate cancer is not yet completely understood, there are a few 
well-established risk factors including age and place of birth. Migration studies support the 
theory of prostate cancer as a multifactorial disease involving, not only genetic factors, but 
also lifestyle and environmental factors. A few studies have investigated the association 
between diet and prostate cancer. Dietary fat, red meat, Vitamin E, selenium and tomatoes are 
examples of nutrients that have been suggested to either increase or reduce the risk of prostate 
cancer. High intake of dietary fat has been suggested to increase the levels of circulating 
androgens and thereby increase the risk of prostate cancer (10). Red and processed meat have 
also been associated with an elevated risk of prostate cancer (11). By contrast, daily intake of 
tomatoes and tomato products seems to reduce the risk (12).  
Family history plays an important role with an approximately two- to three-fold increased 
risk for men with affected first-degree relatives (father, brother, son) (13). The risk generally 
increases with the number of affected relatives. Certain genetic traits have been associated 
with increased risk of developing prostate cancer. It is estimated that around 5% of prostate 
cancers develop from mutations in highly penetrant cancer predisposition genes, such as 
HOXB13, BRCA1 and BRAC2 (14, 15). BRCA1 and BRCA2 are tumor suppressor genes and 
mutations in these genes contribute to a higher risk of early onset of prostate cancer and 
worse prognosis (16, 17). Studies have shown that BRCA2 carriers have a higher risk 
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compared to BRCA1 carriers (18, 19). Patients with BRCA1 and BRCA2 mutations and 
metastatic prostate cancer have recently been shown to have a high response rate to the 
PARP-inhibitor olaparib (20). Although there are a few germline variants that are associated 
with high risk of prostate cancer, the disease more commonly develops as a result of a 
combination of genetic changes and environmental factors or sporadic somatic mutations. 
Genome wide association studies have helped to identify single nucleotide polymorphisms 
(SNPs) associated with prostate cancer. While each SNP alone is associated with a rather 
small risk, combinations of several SNPs may increase the risk significantly. More than 200 
SNPs have been identified, which are estimated to account for around 30% of inherited risk 
of prostate cancer (21, 22).  
 
1.3 CLINICAL FEATURES AND DIAGNOSIS  
1.3.1 Clinical features 
Men with early stage prostate cancer are commonly asymptomatic. As the disease progresses 
the patient may present with lower urinary tract symptoms, such as increased frequency, 
weak stream, nocturia and urgency. Patients with these symptoms often have locally 
advanced disease, which may or may not be curable. Prostate cancer often metastasizes to 
lymph nodes and bone. Liver and lung metastases also occur, although more rarely. Patients 
with advanced disease may present with bone pain, loss of weight and fatigue. S-PSA testing 
combined with digital rectal examination (DRE) are included in the initial diagnostic work-up 
for prostate cancer. If these tests detect an abnormality, the patient is usually further 
examined with ultrasound, core biopsy and magnetic resonance imaging (MRI).  
1.3.2 DRE 
DRE is a fast, safe and cost-effective diagnostic tool and therefore usually recommended as 
routine examination in the diagnostic process of prostate cancer. However, it is dependent on 
the examiner and the result should therefore be interpreted cautiously (23). In a recent 
systematic review the sensitivity and specificity for DRE for prediction of prostate cancer in 
symptomatic patients was 28.6% and 90.7%, respectively (24). The relatively low sensitivity 
indicates that many patients diagnosed with prostate cancer do not have an abnormal DRE. 
Therefore, patients with suspected prostate cancer should be further investigated regardless of 
the DRE result.  
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1.3.3 PSA 
Prostate-specific antigen (PSA) is an enzyme that is produced in the epithelial cells of the 
prostate and secreted into the prostatic ducts. A small amount of PSA enters the circulation. 
In some conditions, including cancer and prostatitis, the basement membrane of the epithelial 
cells is disrupted, which leads to higher levels of PSA in the blood. Therefore, s-PSA is 
usually higher in men with prostate cancer than in those without cancer, although cancer cells 
usually produce less PSA compared to normal epithelial cells. Poorly differentiated prostate 
cancer cells may entirely lose the ability to express PSA and these tumors are often clinically 
aggressive. S-PSA testing was clinically introduced in the 1980s (25), however, until the 
early 1990s it was mostly used for monitoring treatment response in patients with advanced 
prostate cancer. 
1.3.4 MRI 
MRI has become increasingly important in the diagnostic process of prostate cancer. Its 
functions include identification, risk stratification and staging of tumors and improved biopsy 
sampling through MRI guidance. The ability to detect clinically significant tumors through 
multiparametric MRI has improved during the last decade (26). The images are evaluated by 
a radiologist and the level of suspicion of prostate cancer is reported according to the PI-
RADS (Prostate Imaging Reporting and Data System). Furthermore, using MRI-targeted 
biopsies helps to identify and sample suspicious areas of the prostate. Studies have shown 
that when patients undergo MRI followed by targeted biopsies, fewer patients are biopsied 
and more clinically significant cancers are detected (27, 28).  
1.3.5 Core biopsies  
Men with elevated s-PSA are usually further investigated with 8-12 core biopsies, which are 
either targeted or systematic. It is most commonly guided by transrectal ultrasound, although 
MRI targeted biopsies may improve sampling of the clinically most important tumor. The 
biopsies are graded according to the Gleason grading system, which is an important tool in 
the treatment planning process. In addition to Gleason score (GS), the pathology report 
includes number of cores with cancer and cancer length in mm. Extraprostatic extension 
(EPE), seminal vesicle invasion (SVI) and lymphovascular invasion should also be reported 
if present. Biopsies only sample a small fraction of the prostate and may not be representative 
of the overall morphology. Therefore, undergrading of the tumor sometimes occurs. At the 
2014 ISUP consensus conference the grading of prostate cancer was updated (29), which has 
led to better agreement between biopsy and radical prostatectomy (RP) score (30).  
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1.3.6 Liquid biopsies 
Blood samples, containing tumor biomarkers, so called liquid biopsies, could potentially 
remedy some of the problems with representative sampling. If the most aggressive cancer has 
the highest fraction in blood, it may aid multifocal profiling in deciding which genomic 
profile that should be applied for prognostication. However, future studies have to be 
conducted to demonstrate if this is possible or not. Therefore, liquid biopsies may have an 
increasingly important role in the early detection, prognostication and treatment planning of 
prostate cancer. However, in patients with localized disease circulating tumor cells and DNA 
are detected at very low levels (31, 32). Therefore, to perform comprehensive genomic 
profiling, needle biopsies of the prostate will remain an important source to access the 
alterations of the tumor genome.  
1.3.7 The dilemma of prostate cancer diagnostics  
In Sweden, opportunistic s-PSA-screening has been applied in recent decades. This means 
that men have s-PSA tests on their own initiative. Since the clinical introduction of s-PSA 
testing, more asymptomatic patients have been diagnosed with prostate cancer. A 
consequence of increased diagnostic activity is that more patients are diagnosed with 
relatively well-differentiated, clinically insignificant tumors. Treatment with curative intent, 
radiotherapy (RT) or RP, is related to side effects such as urinary incontinence and 
impotence. Men who otherwise would never have been diagnosed with symptomatic prostate 
cancer risk undergoing treatments with lifelong side effects that often impact their quality of 
life. Overdiagnosis and subsequent overtreatment of indolent prostate cancer is therefore a 
great concern. S-PSA has a high false positive rate and an elevated value may be seen in a 
number of conditions other than prostate cancer, such as benign prostatic hyperplasia, urinary 
tract infection and prostatitis. Patients with elevated s-PSA usually undergo core biopsies but 
this procedure is associated with complications, most commonly infections (33). Due to these 
issues, s-PSA-screening in asymptomatic patients has been considerably debated. Several 
studies have been carried out with the purpose to improve the diagnostic process of prostate 
cancer. The STHLM3 study (34), which was published in 2015, evaluated a new model for 
detection of prostate cancer. The test is a combination of plasma protein markers, genetic 
polymorphisms (232 SNPs), and clinical variables. The model was tested in men aged 50-69 
in the Stockholm region and identified clinically significant high-risk cancers, defined as 
cancers with GS of at least 7, with greater specificity than s-PSA alone. As for MRI targeted 
biopsies, this test could reduce unnecessary biopsies, which is highly valuable in a screening 
situation. In an ongoing study the combination of STHLM3 test with MRI and following 
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targeted biopsies is evaluated (35). This model is suggested to further improve the specificity 
in prostate cancer detection and reduce the risk of overdiagnosis. 
 
1.4 TUMOR CLASSIFICATION 
1.4.1 Localization and histological subtypes 
Prostate cancers are usually multifocal with at least 2-3 tumor foci of different histological 
architecture (36, 37). Arora et al found two or more cancer foci in 87% of 115 whole-mount 
prostatectomy specimens (36). In these foci, the GSs were commonly different from the 
overall score of the tumors. The majority of tumors arise in the peripheral zone (PZ) of the 
prostate, but some arise in the transition zone (TZ). Central zone tumors are rarely seen 
unless it is secondarily involved. More than 90% of all primary prostatic tumors are acinar 
adenocarcinomas. Ductal adenocarcinoma, which is often seen in combination with acinar 
adenocarcinoma, is the second most common histologic subtype and associated with poor 
prognosis (38). Other variants of prostatic carcinoma are uncommon and include basal cell 
carcinoma, neuroendocrine tumors and sarcomatoid carcinoma.  
1.4.1.1 Intraductal carcinoma of the prostate  
Intraductal carcinoma of the prostate (IDC-P) is a lumen-spanning proliferation of prostate 
adenocarcinoma cells within pre-existing benign ducts and acini (Figure 2). IDC-P has a 
basal cell layer that is at least focally preserved. It is seen in about 20% of RP specimens and 
almost always together with invasive adenocarcinoma (39). IDC-P without an invasive 
component of adenocarcinoma has only been reported in a few cases (40). Therefore, curative 
treatment is often recommended for men with IDC-P on needle biopsies, even in the absence 
of invasive carcinoma. It has been shown that IDC-P shares several somatic alterations with 
cribriform invasive cancer, suggesting a close association between this feature and invasive 
prostatic carcinoma Gleason grade 4 and 5 (41). However, the International Society of 
Urological Pathology (ISUP) consensus conference in 2014 recommended that IDC-P should 
not be graded (29). A survey study showed that the reporting of IDC-P varies among 
European uropathologists, suggesting that standardization of reporting is needed (42). IDC-P 
is associated with advanced tumors and studies have demonstrated that patients with 
components of IDC-P have a poorer clinical outcome (43-45).  
 
   7 
 
 
 
1.4.2 Gleason grading system 
Morphological grading is an important prognostic factor in tumor pathology. The Gleason 
grading system was established by Donald Gleason in the 1960s (46) and is the most widely 
used grading system for prostate cancer. The grading scale is based entirely on the 
architectural patterns of the prostatic glands. The five basic growth patterns range from l to 5, 
where 1 is the most differentiated and 5 the least differentiated (Figure 3). Adding the 
primary grade (the dominant pattern of the tumor) and the secondary grade (the second most 
frequent pattern) generates the GS. Tumors with higher GS are more aggressive and 
associated with a worse outcome. Over the last decade there has been a significant inflation in 
Gleason grading (47). The system was revised at the ISUP consensus conference in 2005 and 
further revised at another consensus conference in 2014 (29, 48). Morphological criteria were 
updated including the definition of Gleason pattern 4. The use of Gleason patterns 1 and 2 is 
no longer recommended since they do not seem to indicate an outcome different from that of 
Gleason pattern 3 cancers. In addition it was suggested that the GSs should be grouped in 
ISUP grades 1 (GS 2-6), 2 (GS 3+4=7), 3 (GS 4+3=7), 4 (GS 8) and 5 (GS 9-10). These 
Figure 2. Histologic slide showing intraductal carcinoma of the prostate. Prostate  
cancer cells with markedly enlarged nuclei filling up the lumen of prostatic ducts.  
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groups predict prognosis and a scale ranging from 1-5 is also more intuitive for the patients 
(49, 50). 
 
 
 
 
 
1.4.3 TNM-classification 
The most widely used staging system for prostate cancer is the American Joint Committee on 
Cancer (AJCC) tumor, node, metastasis (TNM) system (Table 1). The last edition (8th 
edition) was published in 2018 (51). The TNM stage combined with GS and s-PSA, gives an 
estimate of prognosis and is considered the basis for guiding of treatment decisions in 
prostate cancer patients (52). In addition, the TNM staging system is an important tool in 
clinical research and enables objective comparisons between clinics and countries.  
Table 1. TNM classification of prostate cancer according to the AJCC TNM system 
Category Criteria 
T  (primary tumor)  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent tumor that is not palpable 
T1a Tumor incidental histologic finding in 5% or less of tissue resected 
T1b Tumor incidental histologic finding in more than 5% of tissue resected 
T1c Tumor identified by needle biopsy found in one or both sides, but not palpable 
T2 Organ confined 
T2a    Tumor involves one half of one side or less 
T2b Tumor involves more that one half of one side but not both sides 
T2c Tumor involves both sides 
Figure 3. Cancer cells and gland architecture according to the Gleason grading 
system with grades from 1 (highest differentiation) to 5 (lowest differentiation). 
Reprinted with permission from www.prostate.org.au 
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T3 Extraprostatic extension 
T3a Extraprostatic extension (unilateral or bilateral) or microscopic invasion of bladder neck 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles, such as 
external sphincter, rectum, bladder, levator muscles, and/or pelvic wall 
N (regional lymph nodes)  
NX Regional lymph nodes were not assessed 
N0 No positive regional lymph nodes 
N1 Metastases in regional lymph nodes 
M (distant metastasis)  
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) with or without bone disease 
 
1.5 PROGNOSIS AND PROGNOSTIC FACTORS 
The prognosis of men with prostate cancer varies significantly. The relative 5- and 10-year 
survival of patients with prostate cancer in Sweden is 93% and 88%, respectively (2). 
Currently, many men are diagnosed with low-risk disease, which has little impact on survival. 
Patients with clinically localized disease are usually stratified into three prognostic 
subgroups. This model predicts the risk of biochemical failure after curative treatment based 
on clinical stage, s-PSA and GS. Patients are classified as follows:  
• Low-risk: Stage ≤T2a and s-PSA level ≤10 ng/ml and GS ≤6 
• Intermediate-risk: Stage T2b or s-PSA level >10 and ≤ 20 ng/ml or GS 7  
• High-risk: Stage ≥T2c or s-PSA level >20 ng/ml or GS ≥8 
A large study based on data from the National Prostate Cancer Register (NPCR) reported a 
10-year mortality for non-curatively treated low- and high-risk prostate cancer, ranging from 
under 5% to almost 30%, respectively (53). The median survival for patients with distant 
metastases at diagnosis was previously around 2.5 years (54). However, in recent years many 
new treatments have been introduced for these patients and the median survival has increased 
accordingly. Patients with bone metastases have a better prognosis than men with both bone 
and soft tissue metastases (55). Lung and liver metastases are associated with a poorer 
outcome (56), although these sites are less commonly affected.  
For patients who undergo RP there are a number of postoperative prognostic factors, apart 
from GS, that may be recognized by the pathologist. Examples of unfavorable features are 
perineural invasion, positive surgical margins and EPE including SVI.  
  10 
1.5.1 EPE 
EPE is tumor extension beyond the boundaries of the prostate. EPE is classified as pT3a 
according to the TNM-system and is a well-established risk factor for recurrence after 
prostatectomy (57, 58). Efforts have been made to stratify patients with EPE in prognostic 
subgroups (59, 60). It has been shown that radial extent of EPE predicts prognosis after RP, 
while perineural invasion at the site of EPE and number of sections or foci of EPE does not 
(60). Also, non-focal EPE seems to predict a worse prognosis than that of focal EPE (60, 61).  
1.5.2 SVI 
1.5.2.1 Anatomy of the seminal vesicles and definition of SVI 
The seminal vesicles are paired pear-shaped glands, about 5 cm in length. The seminal 
vesicle consists of a 10-15 cm long coiled tube. The duct of each seminal vesicle joins the vas 
deferens to form the ejaculatory duct. They are located posterior to the base of the urinary 
bladder and anterior to the rectum.  
Locally advanced prostate cancer may infiltrate the seminal vesicles. The incidence and 
prognostic effect of SVI varies remarkably depending on the definition of SVI. Previously, 
tumor cells in the connective tissue surrounding the seminal vesicles was considered 
sufficient for SVI (62). Today, it is generally accepted that invasion of tumor cells in the 
muscular coat of the seminal vesicles is required for this diagnosis (Figure 4) (63-65). 
Further, it has been discussed whether involvement of the intraprostatic portion should be 
considered SVI. Studies have shown that men with invasion restricted to the intraprostatic 
portion of the seminal vesicles have a better prognosis than those with extraprostatic SVI and 
should therefore not be staged as pT3b (66). Accordingly, it was decided at the ISUP 
consensus conference in 2009 that SVI should be defined as cancer invading the muscular 
wall of the extraprostatic part of the seminal vesicles (63). 
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1.5.2.2 Route of invasion  
Various routes of SVI have been described. Villers et al found that the majority of tumors 
invaded the seminal vesicles via continuous spread along the ejaculatory duct (67). They 
reported a minority of cases in which tumor first spread outside the prostate and then invaded 
the seminal vesicles. Only one case in their series had discontinuous isolated foci of tumor in 
the seminal vesicles. Ohori et al further evaluated the mechanisms of SVI and defined three 
different types of invasion (Figure 5) (68). Type 1 involvement had direct spread along the 
ejaculatory duct into the inside of the seminal vesicles. Type 2 was defined as invasion 
through the prostate capsule into the seminal vesicles. This group was further divided into 
two subgroups; type 2a defined as direct extension of prostate cancer between the base of the 
prostate and the seminal vesicles and type 2b defined as retrograde growth of prostate cancer 
along periprostatic nerves. The least common variant, Type 3, had small foci of cancer in the 
seminal vesicle without continuous growth from the primary tumor. Out of 64 patients with 
SVI, 17 (27%), 21 (33%) and 8 (13%) were classified as Type 1, 2 and 3 patterns 
respectively. In 18 patients (28%) it was not possible to distinguish between Type 1 and 2. 
In a recent study by Samaratunga et al the distribution of cancer growth in the seminal 
vesicles was examined (69). They evaluated 56 cases of SVI and found that all but one case 
had invasion to the proximal third of the seminal vesicles. The only case with distal invasion 
in the absence of proximal invasion had lymphovascular infiltration. The authors suggested 
Figure 4. Cancer cells (left) invading the muscular wall of the seminal vesicle. 
The invasion does not involve the mucosa of the seminal vesicle (right).  
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that sampling of the proximal third of the seminal vesicles is sufficient to find practically 
every case of SVI. However, in cases with lymphovascular invasion and absence of proximal 
invasion, the entire seminal vesicles should be examined. 
 
1.5.2.3 Incidence and prognostic significance  
The incidence of SVI in the literature is highly variable, ranging between 3% and 26% (70-
76). It has decreased over the past decades and in recent studies rates between 3% and 7% are 
commonly reported (69, 71, 77). Traditionally, SVI has been regarded as an indicator of poor 
clinical outcome and in early studies almost every patient with SVI experienced biochemical 
recurrence (78, 79). D’Amico et al found that SVI was the most significant pathological 
predictor of s-PSA recurrence with a 2-year s-PSA failure rate as high as 95% after RP (78). 
Others have reported a 5-year s-PSA progression free rate between 14% and 56% (66, 68, 72, 
73, 80, 81). Since the introduction of s-PSA testing patients generally present with more 
favorable clinicopathological features at time of diagnosis, suggesting improved outcome. 
Eggener et al showed that progression free survival after RP had significantly improved 
among men with SVI in the s-PSA era. They reported 4- and 7-year biochemical progression 
free survival rates at 32% and 22% before s-PSA testing compared to 50% and 45% after 
Figure 5. Classification of SVI according to Ohori et al. Type 1. Direct infiltration along 
the ejaculatory duct into the seminal vesicles. Type 2. Invasion through the prostate 
capsule into the seminal vesicles. Type 3. Discontinuous cancer focus separated from the 
primary tumor.  
!!!
1 
2 
3 
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(77). However, in another study it was shown that despite decreasing incidence of SVI, the 
recurrence rate among those tumors remained high with a 5-year biochemical recurrence free 
survival reported at 36.8% and 36.1% before and during the s-PSA era, respectively (71). 
Parameters such as route of invasion, tumor volume, unilateral vs. bilateral involvement of 
the seminal vesicles, surgical margin status, GS and s-PSA level have been used for 
stratification of SVI in prognostic subgroups (64, 65, 68, 73, 74, 82). Ohori et al examined 
the prognostic significance of the different routes of invasion (68). When patients with lymph 
node metastasis were excluded, there was a trend toward better prognosis for patients with 
Type 3 than with other types; however, the difference was not significant (p=0.09). In this 
group, the tumor size was often smaller and positive surgical margins were less commonly 
seen. More recently, others have been unable to confirm the prognostic significance of 
invasion route (64). 
Epstein et al evaluated 45 cases of SVI and found that tumor volume, extent of SVI or 
laterality did not correlate with prognosis in this group (65). The only factors that appeared to 
influence progression were the status of surgical margins and GS dichotomized in GS less 
than 7 vs. 7 or greater, however, the results were not statistically significant. In a more recent 
study by the same group, GS, surgical margin status and vascular invasion were significant 
prognostic factors in multivariate analysis (64). Tefilli et al found that positive surgical 
margins and GS 7 or higher were significant predictors of disease progression analyzing 93 
patients with SVI (82). In addition, patients with preoperative s-PSA less than 10 ng/ml had a 
better clinical outcome. Overall surgical margin status was found to be an independent 
predictor of disease recurrence in multivariate analysis. However, other studies have shown 
that positive surgical margins have no effect on progression in men with SVI (73, 80). 
Salomon et al found preoperative s-PSA and the GS of the prostatectomy specimen to be 
independent prognostic factors, while positive surgical margins did not predict progression 
(73). There is no evidence that bilateral SVI is associated with worse prognosis compared to 
unilateral SVI (64, 65). 
1.5.2.4 Preoperative diagnosis  
Previously, patients diagnosed with SVI preoperatively were usually not considered 
candidates for surgery with curative intentions due to the high failure rate. In recent years, 
however, selected patients with advanced disease are more often recommended surgery (83). 
Recent studies have shown improvements in clinical outcome for patients with adverse risk 
factors, such as SVI, when treated with RP in combination with postoperative RT (84-86). 
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For optimized treatment planning accurate prediction of advanced pathology is crucial. 
Clinical stage, preoperative s-PSA and GS on needle biopsy are often used as predictors of 
the postoperative pathological stage (52, 87-92). SVI is sometimes detected at preoperative 
examination by DRE, radiological imaging or targeted biopsies. In addition, biopsy cores 
positive for cancer at the base of the prostate are associated with higher risk of SVI (93). Yet, 
how to best diagnose SVI preoperatively is not entirely understood.  
Although several studies have shown that seminal vesicle biopsies reliably detect tumor 
invasion, they are rarely used routinely as SVI is a relatively uncommon finding (94-96). 
Consequently, the seminal vesicles are rarely targets for biopsies, but sometimes when a 
biopsy is directed towards the base of the prostate the biopsy accidentally hits the seminal 
vesicle, which may enable a diagnosis of SVI. Invasion of cancer cells in the muscular wall 
of the extraprostatic part of the seminal vesicles is required for diagnosis at biopsies (63). 
Thus, it may be impossible to distinguish between intra- and extraprostatic SVI and 
ejaculatory duct invasion on needle biopsy. EPE is diagnosed on preoperative needle biopsy 
when cancer cells are seen infiltrating adipose tissue (97). Apart from these definitive 
preoperative signs of SVI and EPE, it remains unknown what biopsy characteristics may 
predict pT3a versus pT3b tumors.  
For support in decision making of treatment options, different clinical risk assessment tools 
are used. Clinical nomograms that include multiple risk variables have been developed for 
prediction of pathological stage and disease recurrence. Most of them use a combination of 
the standard predictors of preoperative s-PSA, clinical stage and biopsy GS (52, 87, 92, 98, 
99). Other preoperative biopsy findings including percentage cancer in the biopsy cores and 
percentage of positive cores have been studied, but results are conflicting (89, 91, 100, 101). 
Bostwick et al evaluated length of cancer growth and found that the best preoperative 
prediction of EPE and SVI was provided by a combination of percentage cancer in the 
biopsies, s-PSA and GS (89). In multivariate analysis s-PSA and percentage cancer in the 
biopsy were the most important independent predictors of SVI. Gallina et al developed a 
nomogram for prediction of SVI that included s-PSA, clinical stage, GS and percentage of 
positive biopsy cores (101). In another study percentage of positive cores was not a predictor 
of SVI in multivariate analysis (102).  
MRI becomes increasingly important in the pre-treatment diagnosing of SVI. Studies have 
demonstrated that MRI has a high accuracy in predicting SVI and that the predictive value 
increases when combined with information from nomograms (103, 104). However, MRI 
alone is not sensitive enough to find all cancers with EPE and SVI. A meta-analysis 
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evaluating a total of 5677 patients with SVI showed a sensitivity and specificity of 0.58 and 
0.96, respectively (105). Also, the experience of the radiologist impacts the accuracy of the 
SVI diagnosis (104). However, MRI-targeted biopsies outperform standard prostate biopsy in 
detecting EPE and SVI (106).  
 
1.6 GENOMIC CHANGES IN PROSTATE CANCER  
As for all types of cancer, the development of prostate cancer usually involves genomic 
changes such as point mutations, copy number variations (CNVs) and structural 
rearrangements. Prostate cancer has a relatively low mutation burden, although advanced 
disease show a higher mutational burden compared to localized disease (107). Examples of 
genomic alterations that have been identified in advanced prostate cancer are point mutation 
or copy number gain of the androgen receptor (AR) gene, TMPRSS2-ERG fusion, PTEN loss, 
TP53 mutation, RB loss, MYC gain and BRCA2 loss (108). Most of these somatic alterations 
are overrepresented in metastatic castration resistant prostate cancer (107, 108). The most 
common structural rearrangement detected in prostate cancer is the gene fusion between the 
androgen-regulated gene TMPRSS2 (transmembrane protease serine 2), and a member of the 
ETS transcription factor family (ERG, ETV1 or ETV4), which is present in about half of 
prostate cancers (109-111). This fusion leads to overexpression of the oncogenic ETS 
transcription factor with subsequent development or progression of disease. It has been 
suggested that ERG rearranged cancers are associated with a higher likelihood of disease 
progression (112), however, in a large prospective cohort study ERG overexpression did not 
predict biochemical recurrence or mortality (113). Further, ERG rearrangements have been 
found in PIN, which suggests that this alteration is an early event and unlikely correlates with 
aggressive disease (114). Deletion of chromosome 8p, which contains the tumor suppressor 
NKX3-1, and amplification of chromosome 8q, which harbors the MYC oncogene, has been 
reported in cases with localized GS 7 tumors and metastatic disease (115, 116). 
PTEN is a tumor suppressor gene that is frequently mutated or deleted in prostate cancer. It is 
sometimes altered in localized tumors, although it is more commonly found in advanced, 
castration resistant disease (107, 117, 118). Inactivation of PTEN is associated with poor 
prognosis and therefore early evaluation of PTEN status may be used to distinguish patients 
who need more aggressive treatment (119-122). Alterations in TP53 are sometimes found in 
prostate cancer, especially in metastatic disease (107). As for PTEN loss, patients with TP53 
mutations have a more adverse clinical outcome. Another important gene is SPOP, which is 
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frequently mutated in prostate cancer (123). SPOP mutations lack ETS rearrangements, 
suggesting a distinct molecular class of prostate cancer (123). 
Somatic AR alterations are detected in metastatic castration-resistant prostate cancer as a 
consequence of evolutionary treatment pressure and as expected, very rarely in hormone-
naïve tumors (108). In the metastatic castration resistant state, prostate tumors remain 
dependent on AR signaling. By somatic AR alterations, the cancer develops resistance to 
hormonal therapies (124). New treatments that target the AR (enzalutamid) or production of 
testosterone (abirateron) have been developed and successfully introduced for patients with 
metastatic castration-resistant disease. However, sooner or later the tumor becomes resistant 
to these treatments through additional alterations in AR or by other mechanisms, for example 
through neuroendocrine differentiation (125).  
Since the introduction of next generation sequencing the understanding of the molecular basis 
of prostate cancer has rapidly increased. Many advances have been made in the 
understanding of tumor progression on a molecular level. This enables subclassification of 
the tumors and will be important for personalized medicine. For example, patients with 
intermediate-risk disease and molecular changes indicating poor prognosis may be suited for 
curative treatment instead of active surveillance.  
Genetic susceptibility for developing prostate cancer is further presented in Risk factors. 
 
1.7 HETEROGENEITY AND ORIGIN OF MULTIFOCAL DISEASE 
Prostate cancer is usually a multifocal disease with more than one intraglandular tumor focus 
in 60-90% of cases (36, 126). It has been widely discussed whether separate tumor foci have 
different clonal origins with separate somatic profiles, or if the tumors have a monoclonal 
origin, meaning that a specific clone spread and result in distinct but genetically similar 
tumors. In order to investigate the somatic relations of separate tumor foci, molecular 
characteristics have been mapped by several research groups; majority of them indicating 
clonal independency among separate tumor foci within the same prostate gland (37, 127, 
128). Early studies in this field used methods such as analysis of polymorphic microsatellite 
regions and fluorescent in situ hybridization (FISH) targeting centromeric regions for selected 
chromosomes.  
Cheng et al examined the pattern of allelic loss in patients with separate tumor foci using four 
microsatellite polymorphic markers (three for a putative tumor suppressor gene and one for 
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the BRCA1 gene) (37). In 15 out of 18 patients a random pattern of allelic deletion was 
observed in spatially separated tumor foci. In another early study, FISH was used to study 
numerical chromosomal anomalies in multiple foci of prostatic carcinoma in 40 RP 
specimens (129). A widespread genomic heterogeneity with different chromosomal 
abnormalities was seen within the same prostate gland. More recently, Kobayashi et al 
sampled tumor foci of prostatectomy specimens with laser capture microdissection (LCM) 
and used comparative genomic hybridization for CNV analysis (127). They found that 
separate tumor foci had different CNVs that sometimes overlapped but never were entirely 
identical. In line with previous studies, they concluded that multifocal prostate cancer is a 
polyclonal disease. 
Analyses of the prostate cancer specific TMPRSS2-ERG gene fusion have been used in 
heterogeneity studies indicating a high level of genomic heterogeneity. Mehra et al used 
FISH to analyze TMPRSS2 rearrangement in a total of 93 tumor foci from 43 RP specimens 
(130). Of the 43 cases, 30 (70%) showed TMPRSS2 rearrangement within at least one tumor 
focus. Furthermore, 70% of the rearranged cases showed discrepancy in rearrangement 
pattern in separate tumor foci indicating clonal heterogeneity.  
Although the majority of these studies indicated clonal independence, the methods are not 
sensitive enough to fully understand the somatic relationship between tumor foci. A single 
structural alteration or chromosomal abnormality represents only one event and does not 
provide information on remaining parts of the genome. More recently, different groups have 
used next-generation sequencing in attempts to better understand the molecular background 
of multifocal disease. In genome-wide studies the analysis is not restricted to single events, 
but changes across the entire genome are analyzed. This provides an opportunity to a more 
detailed evaluation of the heterogeneity pattern.  
Lindberg et al performed whole-exome sequencing on multiple tumor foci in four individuals 
(128). The tumor foci did usually not share any of the identified SNVs and their results 
indicate a high level of heterogeneity and somatic independency between foci. In another 
recent study, 89 tumor foci in 41 men were examined and in 76% of cases none of the foci 
shared any point mutations (131). In addition, the few shared mutations were rarely in genes 
that are critical for the development of cancer.  
Although the majority of studies have hinted a multiclonal origin, a few have claimed the 
opposite. Boyd et al performed array-based CNV analysis on 18 cases of clinically localized 
prostate cancer and found identical copy number changes shared in all foci within the same 
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case (132). They suggested that although genomic changes accumulate independently in 
separate tumor foci as cancer progresses, it is unlikely that all foci have the exact same 
genomic changes even if they origin from the same initial clone. Prostate carcinogenesis has 
also been suggested to be a result from a field effect with an abnormal mutational process 
from which prostate cancer develops and clones further branch into subclones (133). 
In a study by Boutros et al, 74 patients with index tumor of GS 7 were examined (115). Copy 
number analysis revealed extensively heterogeneous profiles between patients. Five cases 
were further sampled and subjected to whole-genome sequencing of 2-9 spatially separated 
tumor foci. A pronounced intertumoral heterogeneity was found when analyzing structural 
alteration, CNVs and SNVs. No shared CNVs and very few shared SNVs were observed 
between tumor foci. They further tested a few prognostic markers for intermediate-risk 
prostate cancer to evaluate the concordance between foci. For example, loss of NKX3-1 was 
reported in two of five foci in one of the cases. This indicates that information of genomic-
based prognostic markers from a single focus should be interpreted with caution. They 
concluded that the high degree of intratumoral heterogeneity with difference in driver 
alterations between foci implies a multiclonal origin of prostate cancer. 
The majority of studies that used high-resolution sequencing methods have shown that the 
somatic heterogeneity between foci is high and that genomic alterations rarely are shared 
between foci. Therefore, multifocal prostate cancer is nowadays commonly regarded as a 
multiclonal disease. With new methods it has also been demonstrated that the heterogeneity is 
high within a single tumor focus. In prostate cancer there is often a dominant, high-grade 
index focus that is relied on in prognostication. Index foci have recently been reported to be 
somatically heterogeneous, with many alterations present in subclonal populations (134).  
 
1.8 THE CLONALITY OF METASTATIC PROSTATE CANCER 
Studies on the genomic heterogeneity of prostate cancer and the clonal relationship in 
metastatic disease are important in order to understand the pathogenesis of the disease. In 
addition, it has major implications in the clinical setting as targeted treatments on driver 
genomic changes become increasingly important. In contrast to multifocal localized disease, 
which seems to have a multiclonal origin with separate tumor foci arising independently, 
studies on metastatic disease have indicated a monoclonal origin (107, 116, 135, 136). 
Similar to studies on multifocal disease, this question was previously studied with 
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chromosomal analysis using FISH and CNV analysis by comparative genomic hybridization 
and it was early suggested that a single tumor clone is responsible for progression (129, 135). 
With next-generation sequencing the opportunity to study the clonal relationship between 
primary tumor and metastasis has improved significantly. These high-throughput methods 
may also provide a time-line for somatic events, which is valuable when studying clonality. 
Haffner et al used whole-genome sequencing and followed one case of lethal prostate cancer 
through longitudinal sampling from the primary tumor and its metastases (137). They were 
able to identify genomic characteristics of the metastatic cell clone and traced the origin back 
to a focal area in the primary cancer. Surprisingly, a small focus with a Gleason grade 3 
cancer showed the same genomic alterations as the metastases, such as mutations in PTEN, 
TP53 and SPOP.  
Although the majority of studies have indicated monoclonal seeding of metastases, Gundem 
et al showed by detailed sampling of patients with castration-resistant metastatic disease that 
multiple clones are involved in metastatic seeding (138). In three of ten cases they found that 
more than one subclone from the primary tumor achieved metastatic potential. In this study 
metastasis-to-metastasis was common and occurred by two mechanisms; either through de 
novo monoclonal seeding or through the transfer of multiple clones between metastatic sites.  
The somatic concordance between spatially separate metastases in patients with castration-
resistant metastatic prostate cancer was recently shown to be high (116). In this study 
genomic alterations were recurrent in AR, ERG, TP53, RB1, SPOP, CHD1 and ZBTB16. 
These alterations have previously been reported by others in metastatic disease (107). In 
addition, gain in regions of chromosome 8q, including MYC, and loss in regions of 8p was 
frequently seen. All mutations were not found in every single metastatic deposit, however, 
driver mutations and potential molecular targets were usually present in every metastasis. In 
line with this study, it has been demonstrated that DNA methylations among men with lethal 
metastatic prostate cancer are maintained in all metastases of the same individual (139). 
These studies indicate that tumor sampling from a single metastasis may be representative of 
the important genomic alterations of the cancer.  
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1.9 TREATMENT 
1.9.1 Curative treatment 
Localized disease is classified according to different risk groups (see Prognosis) and 
treatment recommendations are based on the risk category in combination with health state 
and age of the patient. It can be cured either by RP or RT. Both treatments are restricted by 
side effect such as urinary incontinence and erectile dysfunction. Active surveillance is an 
option for patients with low risk disease. Patients with expected survival under 10 years and 
low or intermediate-risk disease may be recommended watchful waiting, which means that 
hormone treatment is initiated when needed without curative intention. A large randomized 
study showed no difference in prostate cancer specific mortality after ten years for men with 
localized disease treated with active surveillance, RT or RP (140).  
1.9.1.1 Surgery 
RP is either done by open retropubic, laparoscopic or robot-assisted laparoscopic approach. 
No significant differences in oncologic or functional outcomes have been shown (141, 142). 
Nerve-sparing technique is used when indicated by features of the tumor, age of the patient 
and preoperative erectile function. If there is a high risk of EPE, nerve-sparing procedure is 
not recommended. The role of pelvic lymph node dissection during RP remains controversial 
(143).  
1.9.1.2 RT 
Curative external RT is given to patients with intermediate- or high-risk localized prostate 
cancer. The radiation techniques have rapidly improved in recent years. Nowadays, RT is 
more precise and higher doses can be given with lower risk of side effects. Patients with 
prostate cancer usually receive up to 78 Gy in 2 Gy fractions, although hypofractionated 
doses have shown similar effect for patients with intermediate-risk tumors (144). HDR (high 
dose rate) brachytherapy is sometimes combined with external radiation. For high-risk 
patients with T3 tumors, RT in combination with hormonal therapy is usually recommended 
over surgery (145). Neoadjuvant and adjuvant hormone treatment is given to the majority of 
patients with high-risk tumors and a few with intermediate-risk tumors.  
1.9.1.3 Adjuvant RT after RP 
Adjuvant RT after RP is given to patients with s-PSA <0.1 ng/ml but high risk for 
postoperative recurrence. The length of positive surgical margin is a prognostic factor for 
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biochemical recurrence after RP (146). In Sweden, adjuvant RT is sometimes considered for 
patients with extensively positive surgical margins (>3mm) without lymph node metastases.  
1.9.1.4 Salvage RT  
For patients with slowly rising s-PSA (two consecutive values over 0.2 ng/ml) after RP and 
suspected local recurrence, salvage RT is commonly recommended. Although the majority of 
patients with local recurrence have positive surgical margins, local recurrence may also occur 
in patients with negative margins. Salvage RT is given with curative intention. If the patient 
has a high GS or s-PSA hormone therapy may be added.  
1.9.1.5 Hormone treatment 
Androgen deprivation therapy (ADT) is used both in curative and palliative treatment. 
Castration is achieved either surgically by orchidectomy or medically through luteinizing 
hormone releasing hormone (LHRH) agonist/antagonist. Antiandrogens (bicalutamide) are 
commonly used in combination with castration as neoadjuvant and concomitant treatment 
during curative RT.  
1.9.2 Palliative treatment 
The vast majority of patients with metastatic prostate cancer initially respond to castration 
therapy, which is always used as a treatment base in the palliative setting. Recent studies have 
shown a survival benefit for patients with metastatic hormone sensitive prostate cancer who 
receive docetaxel or abirateron (147, 148). However, sooner or later the disease progresses to 
a castration-resistant state (149). Mechanisms of resistance include AR overexpression, AR 
mutations and increased intratumoral steroidogenesis (150). Today, there are a number of 
different treatment options for patients with metastatic castration-resistant disease, including 
chemotherapy (docetaxel, cabazitaxel), second-generation antiandrogens (enzalutamide, 
abirateron) and radioisotope (radium-223).  
 
 
 
 
  22 
1.10 SUMMARY 
There is a need of additional biomarkers for treatment stratification of prostate cancer 
patients. Increased knowledge of histological features and genomic changes associated with 
aggressive disease would be helpful for treatment planning. With the stage shift that has 
occurred over the last decades, the incidence of locally advanced prostate cancer has 
decreased. SVI has traditionally been regarded as an ominous prognostic indicator. However, 
the group of cancers with SVI is heterogeneous and not all patients with SVI experience 
recurrence of disease. Further stratification is needed in order to better predict prognosis and 
optimize treatment for this patient group.  
The morphological and genomic profile of clones with metastasizing potential has not been 
fully identified. More studies are needed to describe the characteristics of these clones.  
Prostate cancer is a somatically heterogeneous disease. Multifocal tumors often present 
different molecular profiles in spatially separated tumor foci. Clinical use of predictive and 
prognostic genomic biomarkers becomes increasingly important to optimize and personalize 
treatment. Core biopsy assessment in the initial diagnostic setting is an important step in the 
treatment planning process. In order to rely on the molecular biomarkers from the biopsies it 
is important that there is a high concordance between genomic findings in biopsies and 
prostatectomy specimens. However, it is still unclear how well the preoperative biopsies 
represent the somatically heterogeneous tumor foci in the prostate.  
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2 AIMS 
The overall aim of this thesis was to investigate prognostic factors and genomic heterogeneity 
of pathological features in locally advanced and multifocal prostate cancer. It was further to 
analyze the utility of preoperative biopsies for prediction of somatic aberrations in multifocal 
prostate cancer. The specific aims were:  
 
1. To evaluate the correlation between histopathological variables and the risk of 
biochemical recurrence after RP in men with SVI. 
2. To study the genomic heterogeneity of prostate cancer and its relation to the clonality 
of metastatic disease. 
3. To study the clinical outcome and analyze the preoperative needle biopsy findings in 
patients with SVI compared to patients with EPE alone. 
4. To evaluate the genomic heterogeneity in multifocal prostate cancer and to analyze 
how well the preoperative biopsies represent the somatically different foci found in 
the prostatectomy specimen. 
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3 MATERIAL AND METHODS 
 
3.1 TISSUE COLLECTION AND PREPARATION (STUDY I, II, IV) 
All RP specimens included in Study I, II and IV underwent the same preparation process. The 
specimens were formalin-fixed overnight, inked and totally embedded. Sections were cut 
horizontally at 4 mm thickness and either whole-mounted or cut into 2-6 segments. The 
specimens were then dehydrated and paraffin embedded. Sections were cut at 4 µm and 
stained with hematoxylin and eosin (H&E). Cancer was outlined on the slides with black 
Indian ink.  
3.1.1 Study I 
All patients included in Study I underwent RP at the Karolinska University Hospital between 
May 1998 and December 2005. Patients were excluded if they had received neoadjuvant 
treatment (hormonal or RT) or undergone transurethral resection prior to surgery. Cases with 
unavailable histological slides or clinical follow-up were also excluded. After exclusion 1050 
cases remained for analysis, including 60 cases with SVI. Due to changed operation 
technique during the inclusion period the seminal vesicles were resected completely in 19 
cases and partially in 41 cases. Partial resection was done to shorten operation time and 
reduce the risk of nerve damage.  
3.1.1.1 Protocol and definitions 
Every case with SVI was reviewed according to a prepared protocol. The following features 
were recorded: laterality, route of invasion, distribution in the seminal vesicle wall, extent 
(intraprostatic vs. extraprostatic), diameters of the seminal vesicle tumor deposits, tumor area, 
positive surgical margins in the seminal vesicle, invasion of vas deferens and GS. 
Measurements and definitions of the features are described in detail here: 
• SVI was defined as tumor invasion of the muscle wall of the extraprostatic part of the 
seminal vesicles. When prostatic tissue and seminal vesicle tissue was seen on the 
same slide, it was considered to be intraprostatic seminal vesicle tissue.  
• Laterality was recorded as uni- or bilateral invasion. 
• Route of invasion was evaluated according to the definitions used by Ohori et al (68). 
Type 1 is defined as growth along the ejaculatory ducts into the seminal vesicles. In 
Type 2 there is tumor extension at the base of the prostate into the connective tissue 
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surrounding the seminal vesicle. Type 3 is discontinuous metastases to the seminal 
vesicle.  
• Level of tumor invasion of the seminal vesicle was registered (Figure 6). Tumor was 
present in the muscular wall alone or in combination with invasion of the mucosa 
and/or the connective tissue surrounding the seminal vesicle. Mucosal invasion was 
defined as cancer infiltrating between tubular seminal vesicle glands.  
• The diameters of the tumor area in the seminal vesicle were measured. The first 
diameter was measured from the base to the tip of the seminal vesicle and the second 
perpendicularly to the first.  
• The tumor area was determined using grid paper. The tumor contours were copied 
onto grid paper with one dot per millimeter and all dots within the tumor area were 
counted. The number was used as a surrogate marker for the tumor area.  
• Status of the surgical margins of the seminal vesicles was recorded.  
• Invasion of vas deferens was noted. In some cases the vas deferens could not be 
identified and presence of invasion was considered indeterminable. 
• GS was registered both for the main tumor and for the seminal vesicle component. 
Follow-up data was obtained from patient records at the Karolinska University Hospital. 
Biochemical recurrence was defined as two consecutive s-PSA values ≥ 0.2 ng/ml. S-PSA 
was measured according to a standardized protocol 6-8 weeks after RP and once or twice 
annually thereafter.  
3.1.1.2 Histological evaluation  
All seminal vesicle slides were reviewed first by the author and later together with a senior 
pathologist (Lars Egevad, LE).  
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3.1.2 Study II 
3.1.2.1 Previous study  
In a previously published study, our group analyzed autosomal and mitochondrial DNA of 
prostate cancers (151). Part of the aim was to validate the clonal relationship between primary 
Figure 6. H&E sections of different types of seminal vesicle invasion. (A) Cancer glands (left) invading the 
muscular wall of the seminal vesicle. (B) Muscular wall invasion of cancer cells (left). The seminal vesicle 
mucosa (right) has not been invaded. (C) Prostate cancer glands invading the muscular wall and the connective 
tissue surrounding the seminal vesicle (right). (D) Cancer invasion of the mucosa of the seminal vesicle. 
Cancer glands invade between seminal vesicle glands. (E) Mucosal invasion. (F) Invasion of the intraprostatic 
part of the seminal vesicle. Seminal vesicle (right) and prostate glands (left).  
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tumor and metastases in two cases (one aggressive neuroendocrine tumor with paired bone 
metastasis and one adenocarcinoma with two lymph node metastases) by cellular frequency 
estimation of all SNVs found in those cases. The neuroendocrine tumor was found to have a 
strong monoclonal relationship between the primary tissue and metastasis, with high degree 
of shared mutations. However, in the second patient it was not possible to find a common 
somatic denominator between the fresh-frozen primary tumor tissue obtained after RP (SWE-
54A) and fresh-frozen right/left pelvic lymph-node metastases (SWE-54B/C). Therefore, this 
case became the subject of a more thorough investigation in order to find the specific clone 
responsible for seeding the metastases. The patient and the tumor characteristics are described 
in detail below. 
3.1.2.2 Patient, histology and tissue preparation 
The patient analyzed in Study II underwent RP and pelvic lymphadenectomy at the 
Karolinska University Hospital, Stockholm, in 2011. The preoperative s-PSA was 16 ng/ml 
and biopsies showed an acinar adenocarcinoma of the prostate, GS 4+5=9 with a total cancer 
extent of 6 mm cancer. Postoperative histological examination revealed a bilateral 
adenocarcinoma with GS 4+3=7 and tertiary Gleason pattern 5. The lymphadenectomy 
specimen was received unfixed and fresh tissue was harvested and frozen. Bilateral lymph 
node metastases were found in the histological sections. The main tumor in the RP specimen 
originated from the PZ although a small separate tumor focus was also found in the TZ. The 
postoperative stage was pT3bN1. Forty-five morphologically distinct foci were identified for 
the genomic analysis (Table 2). The spatial localizations of the separate tumor foci are seen in 
Figure 7.  
Table 2. Tissue area harvested with LCM 
Areas Histopathological feature 
1–29 Main tumor 
7–9 Intraductal carcinoma 
30–34 Separate foci in peripheral and transitional zone 
10, 18 Extraprostatic extension 
27–29 Seminal vesicle invasion 
35–39 High grade PIN 
40–42 Atrophy  
43–44 Benign prostatic hyperplasia 
45 Basal cell hyperplasia (with spots of squamous cell metaplasia) 
46 Normal tissue, epithelial cells 
47 Normal tissue, stromal cells 
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The paraffin blocks were serially sectioned at 10-µm and mounted on UV-treated membrane 
slides. The slides were stained with H&E and stored at 4°C before LCM.  
3.1.3 Study IV  
Eleven patients with multifocal disease who had undergone systematic biopsies followed by 
RP at the Karolinska University Hospital between 2011 and 2012 were included in Study IV. 
Figure 7. Whole-mount sections of the prostatectomy specimen examined in Study II. 
Cancer is outlined with black Indian ink. Areas collected with LCM are marked and 
numbered.  
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At least two distinct major tumor foci were observed in every case. In each case, one to three 
biopsy cores with the greatest tumor extent were selected for analysis. Only cores with more 
than 2 mm cancer were analyzed. When possible, cores from both the left and the right side 
of the prostate were included.  
Fresh frozen tissue was harvested from the RP specimens by cutting a horizontal section 
through the prostate gland using a double-bladed knife. The tissue slice was split into smaller 
blocks, embedded in Optimal Cutting Temperature (OCT) compound, snap-frozen in liquid 
nitrogen and stored at -800C. Fresh frozen tissue was sectioned in 5 and 10 µm serial sections 
and a total of 100 µm thickness of the tissue block was collected from every focus. The tumor 
foci were macroscopically dissected and sections collected in a tube. The sample was stored 
at -800C before extraction. The formalin-fixed paraffin-embedded (FFPE) tissue was 
prepared as described above. Both frozen and FFPE sections were stained by H&E. The 
paraffin blocks of the biopsies and the prostate were cut in serial sections at 10 µm and the 
tumor foci were macroscopically dissected. In total, four sections were collected in a tube and 
stored at 4°C before extraction. Control sections of all tissues were examined microscopically 
to verify a ≥25% tumor content. 
The FFPE samples from biopsy and RP specimens were designated BX and RP FFPE, 
respectively, and the frozen samples were labeled RP frozen.  
 
3.2 STUDY POPULATION AND DATA COLLECTION (STUDY III) 
The third study of this thesis was a registry study based on data retrieved from the NPCR, 
which covers 98% of all prostate cancers that are diagnosed in Sweden. Data on clinical and 
pathological features as well as primary treatment is registered in NPCR. In addition, 
information on the preoperative needle biopsies has been recorded systematically since 2009. 
In Study III, data were obtained on all men who were diagnosed with prostate cancer between 
2000 and 2012 and who underwent RP as primary treatment. Patients with stage pT3a and 
pT3b were analyzed and compared. Furthermore, the preoperative needle biopsies of patients 
with pT3a and pT3b who were diagnosed from 2009 to 2012 were analyzed.  
3.2.1 Outcome measurements 
In order to analyze outcome, NPCR data were merged with information from the Swedish 
Cause of Death Registry and Prescribed Drug Registry. Clinical progression was defined as 
initiation of postoperative treatment with RT or ADT. Patients who received treatment within 
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two years after RP were excluded since they possibly were treated with adjuvant intention. 
Patients who received ADT were identified through the Prescribed Drug Registry, which 
registers all prescribed medications retrieved by patients. This register was started in 2005 
and left truncation was therefore needed on this data. Radiation doses less than 60 Gy were 
considered to be palliative treatment. Data on death from all causes and death from prostate 
cancer were retrieved from the Swedish Cause of Death Registry and also used as endpoints. 
 
3.3 LCM (STUDY II) 
One of the challenges of preparing tumor tissue is to separate and collect the specific cells of 
interest from the surrounding tissue. This issue is particularly pronounced in prostate 
carcinoma since the tissue usually is very heterogeneous and tumor glands often infiltrate 
between normal glands. Macrodissection may lead to a low tumor purity, which aggravates 
analysis of data. LCM allows for isolation of specific cells or glands from tissue under direct 
microscopic visualization. Through this method it is possible to ensure a high tumor purity of 
the specific cells of interest. LCM was developed at the National Cancer Institute of the 
National Institutes of Health in Bethesda, USA in the late 90s (152). A thermoplastic 
membrane is placed over a tissue section, on which the cells of interest adhere using a pulse 
from an infrared laser. This film is then directly transferred to for example a buffer for 
downstream analysis. 
In Study II a LCM instrument from Zeiss was used for microdissection. The tissue sample is 
cut and catapulted from the slide to a microfuge tube cap that collects the tissue. The slides 
were examined under the microscope and the glands of interest marked and dissected into the 
adhesive capsule (Figure 8). During microdissection the original slides were continuously 
examined under a microscope to ensure that the right glands were harvested. In a few cases 
the area was examined, marked and cut in the LCM microscope but instead of being 
catapulted into the adhesive capsule, it was transferred to the capsule using a sharp knife. 
This method was used to yield larger amounts of DNA in cases where the tumor cells were 
tightly packed to ensure a high tumor purity of the samples. All tumor samples were 
estimated to contain 80-100% tumor cells. Samples were collected according to Table 2. Six 
foci were excluded because the morphology could not be confirmed after re-cutting of the 
blocks. Photographs were taken before and after dissection. Areas that showed a slightly 
changed morphology compared with the original slides were always discussed with a senior 
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pathologist (LE). The dissected samples were kept in a box protected from light at room 
temperature (18–22°C) until they were prepared for DNA extraction.  
 
 
 
 
 
3.4 DNA EXTRACTIONS (STUDY II AND IV) 
3.4.1 Study II 
DNA was extracted using QIAamp DNA Micro Kit (Qiagen) according to the manufacturer’s 
instructions. After extraction the samples were eluted in RNAse-free water and stored at 
−18°C before library preparation and sequencing. DNA concentrations were measured using 
a Qubit 2.0 fluorometer. The DNA amounts of the samples ranged between 1.3 to 51.6 ng, 
with highest amounts in the macrodissected areas. Six samples were lost due to 
manufacturing flaws (leakage from the adhesive capsules during extraction). 
Figure 8. Pictures from the LCM process. (A) Glands subjected for LCM before cutting. (B) 
Small areas with tumor cells are drawn and cut with the laser. (C) The pieces with tumor cells 
have now been cut out and catapulted into an adhesive capsule. (D) Tumor samples collected 
in the adhesive capsule.  
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3.4.2 Study IV 
In Study IV a total of 69 tumor samples were extracted for DNA. The samples consisted of 
22 FFPE biopsies, 25 FFPE tumor foci and 22 fresh frozen tumor foci. DNA extraction was 
performed using the Allprep FFPE kit (Qiagen) according to the manufacturer’s protocol.  
 
3.5 LIBRARY CONSTRUCTION, SEQUENCING AND BIOINFORMATICS 
(STUDY II AND IV) 
3.5.1 Study II 
The sequencing libraries for the fresh-frozen primary tumor tissue (SWE-54A) and the 
right/left lymph-node metastases (SWE-54B/SWE-54C) were previously prepared and 
processed (151). The construction of libraries for microdissected tissues was done using a 
ThruPLEX kit (Rubicon Genomics, USA) according to a standard protocol.  
Low-pass whole-genome sequencing was done to detect break-point regions (BPRs). A BPR 
is a region where the sample sequence alters from the reference sequence and marks a start of 
an amplification or a deletion event. A total of 385 BPRs were identified, which were used 
for the construction of a somatic phylogenetic tree. Nine tumor samples contained fewer than 
five BPRs and were excluded. In addition, eleven foci were lost during tissue harvesting, 
library preparation or quality control of the data. In total, 28 samples, including SWE-A/B/C, 
were further analyzed. The somatic relationship between every tumor foci and the metastases 
was presented in the phylogenetic tree. The right and left lymph node showed a high degree 
of similarity with 80% (62 events) of the BPRs shared between samples.  
3.5.2 Study IV  
The library preparation and sequencing steps were done in collaboration with SciLifeLab, 
Solna, as previously described (153). Briefly, DNA was used to create sequencing libraries 
using ThruPLEX kit (Rubicon Genomics, USA) and DNA profiling was performed with in-
solution hybridization capture and targeted sequencing (SeqCap EZ system, Roche 
Nimblegen, USA). Targeted sequencing of 289 genes was done. Downstream bioinformatics, 
including basic quality control and identification of mutations, CNVs and structural 
variations, were also performed as described (153). Mutations and structural variations were 
manually annotated for each case for the identification of putative driver alterations.  
Tumor samples that shared a CNV pattern or at least one driver alteration with allele fraction 
≥ 0.25 * tumor purity were considered to have a common somatic denominator, i.e. they were 
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classified as the same cancer. In a few samples it was hard to draw conclusions on somatic 
denominator due to insufficient amount of DNA, low coverage (<100x) and/or low tumor 
purity (<20%). Variants in samples with tumor purity <0.2 were considered clonal with an 
allele fraction ≥0.05. Tissues that did not harbor any clonal variant, but shared non-clonal 
events with another cancer, were designated as a possible match.  
 
3.6 IMMUNOHISTOCHEMISTRY (STUDY II) 
Immunohistochemistry is a method for detection of proteins in tissue sections. The method 
was used in Study II, which together with morphological evaluation confirmed the diagnosis 
of IDC-P. The basic principle of immunohistochemistry involves antibodies binding 
specifically to antigens in the tissue. This binding can be visualized in several ways. Most 
commonly, the antibody is conjugated to an enzyme, which allows for visual detection when 
activated.  
One of the major criteria for the diagnosis of IDC-P is entire or partial preservation of the 
basal cell layer. Therefore, immunohistochemical staining was performed for a typical basal 
cell marker, p63, and alpha-methylacyl-CoA-racemase (AMACR), commonly strongly 
expressed in prostate cancer. A positive staining for p63 in a basal cell distribution combined 
with a positive staining for AMACR in luminal cells would be suggestive of the diagnosis 
IDC-P. The staining was done according to standard protocols. 
 
3.7 STATISTICAL ANALYSES (STUDY I AND III) 
Statistical analyses of Study I and III were performed using the program R statistics (The R 
Foundation for Statistical Computing, Vienna, Austria). Cox regression models were used for 
time-to-event analyses of biochemical recurrence in Study I and death from prostate cancer, 
death from any cause or clinical progression in Study III. Wilcoxon’s signed-rank test was 
used for paired comparisons in Study I. Hazard ratios were calculated and Kaplan-Meier 
curves were created to compare progression-free survival between patients with and without 
SVI and mucosa invasion. In Study III missing values from the registry data were imputed 
using multiple imputation based on chained equations (154). Five imputation datasets were 
created. pT stage was imputed for true missing values and in cases with no distinction 
between pT3a and pT3b. The means of the imputation datasets were used for generating 
Kaplan-Meier curves to compare patients with tumor stage pT3a and pT3b. In order to 
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evaluate any change in clinical outcome over time, the progression-free survival of patients 
with pT3a and pT3b tumors was analyzed for each year from 2000 to 2012. Mann–Whitney 
U test and chi square test were used to compare biopsy data between the different stage 
groups. In both studies, p-values of less than 0.05 were considered statistically significant. 
 
3.8 ETHICAL CONSIDERATIONS 
Study I-IV were approved by the Regional Ethic Review Board in Stockholm (2006/1014-31, 
2010/710-31/2, 2013/153-31, 2015/0147-32). 
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4 RESULTS AND DISCUSSION 
 
4.1 STUDY I: CANCER INVASION TO THE SEMINAL VESICLE MUCOSA IS 
ASSOCIATED WITH A HIGH RISK OF BIOCHEMICAL RECURRENCE 
4.1.1 Main findings and general discussion 
In the first study we reviewed a consecutive series of RP specimens from the Karolinska 
University Hospital to identify cases with SVI. Histopathological features of SVI were 
analyzed in order to find possible prognostic factors. Of the 1050 RP cases reviewed, 60 
(5.7%) had SVI, which is in line with other contemporary studies, reporting incidences of 
SVI in around 3-9% of RP specimens (71, 74). The incidence of SVI has decreased during 
the last decades as a result of earlier detection of cancer since the introduction of s-PSA 
testing (71). A current trend towards surgery in patients with more advanced stages may, 
however, again increase the proportions of patients with stage pT3.  
SVI was associated with a poor prognosis (HR 1.7, 95% CI 1.1-2.6, p=0.015), with 
biochemical recurrence in 38.3% of cases. The slope of the Kaplan-Meier curve was 
relatively steep the first 20 months for patients with SVI, but then leveled out and became 
more or less parallel with the curve of patients without SVI (Figure 9). This indicates there is 
an increased risk of early recurrences in pT3b disease, although the reason for this has not 
further been evaluated. It would be of interest to study characteristics of the group of men 
with early recurrences.  
                                 
 
 
Figure 9. Kaplan-Meier curve estimating the recurrence-free survival of patients with and 
without seminal vesicle invasion. HR 1.7 (95% CI 1.1–2.6, p = 0.015). In total, 60 patients 
with seminal vesicle invasion and 990 patients without seminal vesicle invasion were 
analyzed.  
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SVI of prostate cancer is a well-established risk factor for biochemical recurrence after RP, 
which was confirmed in this study. However, the mechanism behind its prognostic 
significance remains unknown. One possibility is that the seminal vesicle is a favored site for 
further tumor cell dissemination. Potter et al suggested that the dismal prognosis was related 
to occult lymph node metastases missed in the routine microscopic examination, but they 
were not able to confirm their hypothesis by immunohistochemical and molecular methods 
(155). Another proposal is that the tumor cells require certain characteristics in order to 
invade the seminal vesicles, such as the ability to infiltrate another tissue type. In that case, 
invasion of the seminal vesicles may be considered a surrogate marker for tumors with 
aggressive potential. In our study the seminal vesicle component always contained the highest 
Gleason pattern present in the main tumor, and a GS lower than 7 was never seen in the 
seminal vesicle component (Figure 10). It has been suggested that the poorer clinical outcome 
in patients with SVI depends on a higher GS. However, SVI usually remains a significant risk 
factor in multivariate analyses when adjusting for GS (64).  
 
 
 
 
 
Intraprostatic invasion of the seminal vesicle was found in 2.2% of cases (23 of 1050) and 
was not associated with risk of recurrence. This is in line with previous studies reporting that 
the prognosis of men with intraprostatic SVI is not as poor as that of men with extraprostatic 
SVI (66). Our finding supports the recommendation issued by the 2009 ISUP Consensus 
Conference that tumor invasion of the muscle wall of the extraprostatic part of the seminal 
vesicles is required for stage pT3b (63).  
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Figure 10. Distribution of GS in the main tumor and the SVI component. Blue staple: Main 
tumor. Red staple: SVI component. In the majority of cases the SVI component had the same 
GS as the main tumor. A GS lower than 7 was never seen in the seminal vesicles.  
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We found that invasion of the seminal vesicle mucosa was associated with a poor clinical 
outcome (HR 4.2, 95% CI 1.2-14.2, p=0.021) (Figure 11) and only three of 19 men with 
muscle wall invasion alone had s-PSA relapse. To our knowledge, this has never previously 
been reported. In line with the discussion above, it could be argued that the mechanism 
behind the poor outcome for men with mucosal invasion is related to certain characteristics 
required for the infiltration of this structure. Mucosal infiltration was seen in 41 out of 60 SVI 
cases (68.3%), and was always accompanied by muscle wall invasion. Thus, when reading 
seminal vesicle slides focus should be on examining the muscular wall. This is helpful for the 
pathologist since efforts on thoroughly looking for small cancer deposits in the mucosa seem 
unnecessary. 
 
                            
 
 
 
Apart from mucosa invasion, neither of the other features evaluated correlated to prognosis. 
Among the routes of invasion, we found Type 1 (83.3%) to be the most common, while Type 
3 was only seen in two cases. The uneven distribution of invasion routes precluded statistical 
analysis of their prognostic impact. However, the two Type 3 cases did not invade the 
seminal vesicle mucosa and none of them recurred.  
 
Figure 11. Kaplan-Meier estimates of recurrence-free survival stratified by 
presence or absence of mucosa invasion among patients with SVI. HR 4.2 (95% 
CI 1.2–14.2), p = 0.021. 
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4.1.2 Definition of mucosa 
There is no generally acknowledged definition of the mucosa. However, in most cases there 
is a fairly well-defined muscle wall in the outer layers of the seminal vesicle, contrasting 
against the mixture of connective tissue and some smooth muscle strands seen between the 
lobules of mucosal glands. In our study, invasion of the mucosa was defined as cancer 
infiltrating between tubular seminal vesicle glands, i.e. above a line touching the base of the 
glandular lobules. Invasion within the epithelium was not required for diagnosis of mucosa 
invasion and would rather be defined as pagetoid spread. As the boundary between mucosa 
and muscle wall sometimes is poorly defined, the introduction of routine reporting of 
mucosal invasion of SVI in clinical practice may need to be preceded by reproducibility 
studies.   
4.1.3 Limitations 
There is always a risk of misleading results in a subgroup analysis with small number of 
cases. However, the number of cases with SVI evaluated in this study is high compared to 
other contemporary series. As the diagnostic process of prostate cancer has developed, the 
patients are usually diagnosed at an earlier stage and therefore it is difficult to collect large 
series with adverse pathological features such as SVI. Furthermore, analysis of the prognostic 
difference between presence versus absence of seminal vesicle mucosa invasion is a 
dichotomous split of the SVI group in reasonably large subgroups. Nevertheless, more studies 
from other centers are needed to validate the results before including mucosal invasion in 
reporting guidelines. 
Early in the study, the entire seminal vesicles were routinely removed at surgery, but later the 
operation technique was changed to obtain shorter operation time and decreased risk of nerve 
damage. Therefore, the seminal vesicles were resected completely in 19 cases and partially in 
41 cases, in which the tips of the seminal vesicles were not removed. This may have 
influenced the results of our study since it is difficult to analyze route of invasion in cases 
with partial resected seminal vesicles. However, the base of the seminal vesicle was always 
removed and since Type 3 invasion is a rare finding this is not likely to influence the results 
of the study. Also, the main finding in this study was the prognostic significance of mucosal 
invasion, which is unlikely affected by partial or complete resection of the seminal vesicles. 
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4.2 STUDY II: IDC-P MAY HAVE THE POTENTIAL TO GIVE RISE TO 
METASTASES  
4.2.1 Main findings 
In the second study of this thesis the aim was to evaluate the genomic aberrations of 45 
regions of a prostatectomy specimen and compare them with the genomic aberrations found 
in the lymph node metastases. This study is based on another report in which initial profiling 
of the primary tumor did not closely match the genomic characteristics of the lymph node 
metastases (151). Therefore, this case was examined much more closely and the primary 
prostatectomy specimen was divided into 45 morphologically distinct regions. Analysis of 
genomic breakpoints was done to reconstruct phylogeny compared to the metastatic lesions. 
Eleven areas were lost during tissue harvesting, library preparation or quality control of the 
data, and another nine foci contained less than five BPRs and were excluded. In total, 25 
areas were successfully analyzed. In total, 385 BPRs were found in two or more tumor areas 
and used to construct the phylogenetic tree. 
Interestingly, we found that the areas somatically most closely related to the lymph node 
metastases were three areas with IDC-P. We verified the diagnosis using 
immunohistochemistry for p63 and alpha-methylacyl-CoA-racemase (AMACR). The areas 
with IDC-P had either a complete or fragmented basal cell layer, which confirms the 
morphological diagnosis of IDC-P (Figure 12). 
 
   
 
 
 
Figure 12. Histological slides of IDC-P (area 8 in the peripheral zone). (A) H&E staining, 
20X lens magnification. (B) The same area with immunohistochemical staining for p63 
(brown) and AMACR (red), 20X lens magnification.  
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As seen in the phylogenetic tree, another area (21_PZ_T1) was also closely related to the 
metastases and the areas with IDC-P (Figure 13). This focus was located at some distance 
(Figure 14) but showed perineural invasion. Area 17 also showed a relatively high degree of 
similarity with the IDC-P components and this area was located between area 21 and the 
IDC-P areas (Figure 14). One possible explanation is that the tumor cells of area 17 gained 
the ability to spread throughout the ducts and along the nerves and became aggressive by this 
mechanism. These features may have enabled the tumor to colonize other part of the prostate 
and spread to lymph nodes. As reported previously (151), the fresh-frozen tumor sample from 
the primary tumor, annotated SWE-54A, did not share any somatic denominator with the 
metastases. However, in this study we found that one of the analyzed areas (20_PZ_T1) had a 
high degree of overlap in BPRs with SWE-54A and shared 83% of its BPRs (Figure 15). This 
Figure 13. (A) Phylogenetic tree showing the somatic similarity between the tumor areas and the metastases. 
(B) Samples were colored according to the proportion of BPRs shared with the lymph-node metastases. 
SWE-54A (primary fresh-frozen tumor sample), SWE-54B (right fresh-frozen lymph-node metastasis) and 
SWE-54C (left fresh-frozen lymph-node metastasis) represent the tissues previously profiled. Tumor regions 
are annotated according to area, zone, focus and in some cases additional label. TZ = transition zone; PZ = 
peripheral zone; IDC = intraductal carcinoma; EPE = extraprostatic extension; SVI = seminal vesicle 
invasion. 
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is not surprising as SWE-54A was macroscopically sampled from the same region as the 
tumor area located in the posterior part of the PZ.  
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Figure 14. Overview of the whole-mount sections and somatic similarity to the metastases 
for each area. Description of each area is available in Material and Methods (Table 2). 
Areas that were lost during sample preparation or quality control are colored light grey. 
Areas that contained fewer than 5 BPRs were not included in the phylogenetic analysis 
and colored dark grey.  
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4.2.2 Genomic evidence for IDC-P as an adverse prognostic factor 
IDC-P is commonly associated with adverse prognostic findings on RP such as high GS, high 
volume and high stage. Also, it is an independent prognostic factor of clinical outcome (44, 
156). It has been demonstrated that IDC-P in diagnostic biopsies is strongly associated with 
metastatic disease after external beam RT (157).  
A few studies have been carried out on the molecular background of IDC-P. One study 
evaluated loss of heterozygosity (LOH) using 12 polymorphic microsatellite markers 
frequently lost in prostate cancer. They found that LOH was present in 60% of IDC-P, 
whereas it was seen in 29% of Gleason pattern 4 cancers and absent in Gleason grade 3 
cancers (158). In a study by Lotan et al cytoplasmic PTEN loss was identified in 84% of 
IDC-P and none of the cases with high-grade PIN (159). As LOH is a marker of allelic 
instability and PTEN loss is associated with aggressive tumor features both studies provide 
plausible molecular explanation for why IDC-P is associated with poor clinical outcome. 
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Although a few studies have shown certain molecular traits of IDC-P that may be correlated 
to poor prognosis, our study is the first to show that this lesion actually has metastatic seeding 
potential. This finding supports previous studies on IDC-P as an indicator of adverse 
prognosis, but also indicates that IDC-P should be reported when found in the RP specimen. 
4.2.3 Reporting of IDC-P 
As IDC-P has been shown to correlate with aggressive tumors it should always be reported 
when found on diagnostic biopsies, especially when seen without invasive cancer or with 
only low-grade cancer (160). In these cases the low-grade tumor is likely not representative 
of the overall tumor grade. Reporting of IDC-P is probably most important in pre-treatment 
biopsies. Our finding that metastases were somatically most similar to the IDC-P component 
suggests a metastatic capacity. It is possible that tumors with an IDC-P component should be 
treated more aggressively. Therefore, it is important that pathologists recognize and report 
this feature correctly. Several diagnostic criteria have been suggested for IDC-P. Guo et al 
reported the most commonly used in 2006 (43). According to this study IDC-P should be 
defined as lumen-spanning intraductal proliferation of atypical epithelial cells with partly or 
completely preserved basal cell layer in combination with either: (1) solid or dense cribriform 
patterns or (2) loose cribriform or micropapillary patterns with either marked nuclear atypia 
(nuclear size 6x normal or larger) or comedonecrosis. This definition is, however, rather 
unclear. The authors did not justify the 6x cut-off for nuclear enlargement and did not specify 
whether the nuclear area or diameter should be considered when determining the size. This 
has led to considerable confusion among uropathologists (42). As a consequence the 
interobserver reproducibility of IDC-P is low, even among experts in uropathology (161).  
4.2.4 Somatic heterogeneity 
This study clearly demonstrates the problems with bulk sampling of prostate tumors when 
mapping the clonality of metastatic disease. A previous study from our group failed to 
establish a somatic relationship between the primary tumor and metastases, possibly because 
of the sampling technique (151). Many studies have shown that there is an enormous 
heterogeneity both between tumor foci and within a single tumor focus of the prostate (134, 
162). These studies clearly demonstrate the importance of a more sophisticated sampling. In 
this study we show that it is possible to identify the metastasizing tumor clone if the samples 
are microdissected. This is important both for mapping of the metastatic pattern of the tumor 
and for identification of aggressive clones.  
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4.3 STUDY III: STAGE PT3B PROSTATE CANCER HAS A POOR PROGNOSIS 
AND A HIGH TUMOR BURDEN ON PREOPERATIVE NEEDLE BIOPSIES 
COMPARED TO PT3A CANCER 
4.3.1 Main findings 
In Study III we retrieved information from the NPCR for the evaluation of the clinical 
outcome of men with stage pT3b compared to men with stage pT3a after RP. We did this to 
examine the prognostic significance of the seminal vesicle component among tumors 
extending beyond the boundaries of the prostate. In addition, we analyzed preoperative 
biopsy data to correlate biopsy pathology with SVI and EPE. In total, we evaluated 31.415 
patients diagnosed between 2000 and 2012 and treated with RP. Out of these patients, 4063 
(12.9%) and 1371 (4.4%) were staged as pT3a and pT3b, respectively. In 1163 patients no 
distinction was made between pT3a and pT3b when registered and these tumors were 
therefore listed as stage pT3 only. Patients with stage pT3b tumor had in general higher s-
PSA at diagnosis and higher GS at RP (Table 3). They also were more likely to receive 
adjuvant RT and/or ADT. 
Table 3. Clinical and pathological features of patients with stage pT3a and pT3b 
 pT3a (n=4063) pT3b (n=1371) P value 
Median follow-up time, RT, years (IQR) 5.3 (3.4-9.7) 5.0 (3.2-9.0) 0.006* 
Median follow-up time, ADT, years (IQR) 5.6 (3.5-10.1) 5.4 (3.2-9.7) 0.073* 
Median follow-up time, death, years (IQR) 5.7 (3.7-10.2) 
 
5.4 (3.5-9.9) 0.047* 
Median s-PSA at diagnosis, ng/ml (IQR) 7.4 (5.3-11.0) 9.2 (6.2-14.0) <0.001** 
Year of diagnosis, n(%)   <0.001*** 
2000-2003 875 (21.5) 276 (20.1)  
2004-2006 966 (23.8)  266 (19.4)  
2007-2009 727 (17.9) 288 (21.0)  
2010-2012 1495 (36.8) 541 (39.5)  
Median age at RP, years (IQR) 64 (60-67) 65 (61-68) <0.001** 
Age at RP, years, n (%)   <0.001*** 
<55 302 (7.4) 79 (5.8)  
55-59 703 (17.3) 183 (13.3)  
60-64 1202 (29.6) 377 (27.5)  
65-69 1390 (34.2) 508 (37.1)  
≥70 466 (11.5) 224 (16.3)  
RP-GS, n (%)   <0.001*** 
2-6 1001 (24.6) 103 (7.5)  
3+4 1636 (40.3) 384 (28.0)  
4+3 899 (22.1) 418 (30.5)  
7 1 (0) 0 (0)  
8 301 (7.4) 212 (15)  
9-10 154 (3.8) 226 (15.5)  
Missing 71 (1.7) 28 (2.0)  
Adjuvant RT, n (%)   <0.001*** 
Yes 806 (19.8) 455 (33.2)  
No  3257 (80.2) 916 (66.8)  
Adjuvant ADT, n (%)   <0.001*** 
Yes 154 (3.8) 159 (11.6)  
No 3909 (96.2) 1212 (88.4)  
*Log-Rank test, **Mann-Whitney U test, ***Chi square test. RT, Radiotherapy; ADT, Androgen deprivation therapy; RP, 
Radical prostatectomy; RP-GS, Radical prostatectomy-Gleason score; s-PSA, serum prostate specific antigen; IQR, 
Interquartile range.  
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In multivariate analysis, adjusting for year of diagnosis, age, biopsy grade and s-PSA, 
patients with stage pT3b had a higher risk of death of prostate cancer (HR 2.3, 95% CI 1.5–
3.3, p<0.001) and death from any cause (HR 1.5, 95% CI 1.2-1.8, p<0.001) compared to 
patients with stage pT3a (Table 4) (Figure 16). Excluding patients who received adjuvant 
treatment, they were also more commonly treated with post-operative RT or ADT, indicating 
clinical recurrence. Although patients with stage pT3b tumors had a higher risk of clinical 
recurrence, the disease specific survival of this patient group was surprisingly high (Table 5). 
After six years, prostate cancer specific survival of patients with pT3a and pT3b tumors was 
98% and 94%, respectively.  
Table 4. Clinical outcome patients with stage pT3a and pT3b 
Endpoint Unadjusted 
HR (95% CI) 
Adjusted  
HR (95% CI) 
All-cause mortality   
pT3a 1.0 (Ref.) 1.0 (Ref.) 
pT3b 1.8 (1.5-2.1) 1.5 (1.2-1.8) 
PCa-specific mortality   
pT3a 1.0 (Ref.) 1.0 (Ref.) 
pT3b  3.0 (2.1-4.2) 2.3 (1.5-3.3) 
Treatment-free survival (RT)   
pT3a 1.0 (Ref.) 1.0 (Ref.) 
pT3b 1.4 (1.2-1.7) 1.5 (1.4-1.7) 
Treatment-free survival (ADT)   
pT3a 1.0 (Ref.) 1.0 (Ref.) 
pT3b 3.5 (2.9-4.3) 3.0 (2.5-3.7) 
 
 
 
Table 5. Prostate cancer specific survival for patients with stage pT3a and pT3b 
Time since radical prostatectomy 
Year of 
radical 
prostatectomy 
One year Two years Three years Four years Five years Six years 
 pT3a pT3b pT3a pT3b pT3a pT3b pT3a pT3b pT3a pT3b pT3a pT3b 
2000 100 100 100 100 100 100 99 98 99 96 99 96 
2001 100 99 100 99 100 99 99 94 99 94 98 93 
2002 100 100 100 99 99 97 99 97 99 96 99 96 
2003 100 100 99 100 99 98 99 96 98 94 98 92 
2004 100 99 99 99 98 98 98 97 98 96 98 94 
2005 100 100 100 100 99 97 99 97 99 96 99 93 
2006 100 100 99 99 99 97 98 97 98 96 97 95 
2007 100 99 100 99 99 97 99 97 98 96 98 93 
2008 99 100 99 99 98 98 97 97 97 97 97 94 
2009 100 99 100 98 100 97 99 96 99 94   
2010 100 100 99 98 99 96 99 95     
2011 100 100 100 100 100 99       
2012 100 100 99 100         
All years 100 100 99 99 99 98 99 97 98 96 98 94 
Cox regression models evaluating prognosis of men with pT3b compared with men with pT3a. All 
comparisons: p<0.001. Adjusted: Adjusted for age at RP, year of diagnosis, biopsy GS and s-PSA. RT, 
Radiotherapy; ADT, Androgen deprivation therapy.  
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In this study we also evaluated the preoperative biopsy findings among patients with stage 
pT3a vs. pT3b. This was done to see if there were any significant differences in preoperative 
findings between the two stage categories. We found that patients with pT3b tumors had a 
greater tumor burden in their biopsies, as analyzed by total cancer length, greater number of 
positive cores and higher percentage of GS 8-10 (Table 6). 
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Figure 16. Kaplan-Meier curves showing the survival, by endpoint, between patients with stage pT3a and pT3b 
tumors. (A) Initiation of postoperative radiotherapy. (B) Initiation of androgen deprivation therapy. (C) Death 
from any cause. (D) Death from prostate cancer.  
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Table 6. Biopsy characteristics of pT3a, pT3b and all pT3 	   	   pT3a (n=1979)	   pT3b (n=715)	   pT3 (n=372) P value 
Median linear cancer extent, mm (IQR)	   	   14 (6-27)	   24 (11-45)	   15 (6-32) <0.001* 
Median number of positive biopsies (IQR)	   	   4 (2-6)	   5 (3-7)	   4 (2-6) <0.001* 
GS at diagnosis, n (%)	   	   	   	     
2-6	   	   602 (30)	   96 (13)	   125 (34) <0.001** 
3+4	   	   794 (40)	   240 (34)	   123 (33)  
4+3	   	   350 (18)	   183 (26)	   74 (20)  
8	   	   164 (8)	   112 (16)	   31 (8)  
9-10	   	   65 (3)	   83 (12)	   16 (4)  
Missing	   	   4 (0)	   1 (0)	   3 (1)  
* Mann-Whitney U test; ** Chi square test 
 
4.3.2 General discussion 
In this study we confirmed that patients with pT3a disease have a more favorable prognosis 
compared to men with stage pT3b. In both stage categories the cancer cells have acquired the 
ability to invade periprostatic tissue, which demonstrates their aggressive phenotype. In line 
with previous literature the invasion of the seminal vesicles was associated with a poorer 
clinical outcome compared to EPE alone. Palliative doses of RT were excluded in the study 
and therefore RT as endpoint should be interpreted as a surrogate marker for local 
recurrences. Both castration therapy and anti-androgens are included in the concept of ADT 
and the initiation of ADT could be a reflection of both local recurrence and distant metastatic 
disease. Hormone therapy is usually not combined with salvage RT. However, this is 
considered for some patients with adverse findings on the RP and relatively high s-PSA. 
When there is suspicion of disseminated disease, treatment with bicalutamide and/or medical 
or surgical castration is usually initiated. Our data indicate that patients with SVI have a 
higher risk of both local recurrences and metastatic disease compared to patients with EPE 
alone. The findings may also reflect that these patients are more likely to be offered salvage 
RT, despite the risk that the disease has already spread to other sites.  
We excluded patients who received RT and/or ADT within two years after RP as they 
possible were treated with adjuvant intention. The exclusion of these patients may introduce a 
selection bias since patients with the most adverse findings (higher s-PSA, higher grade, more 
extensive positive surgical margins, etc.) are more likely to receive adjuvant or salvage 
treatment after surgery. Exclusion of this group would make the overall prognosis seem more 
favorable. On the other hand, including all patients would also be problematic since the 
addition of adjuvant treatment would be classified as recurrence, leading to an overestimation 
of clinical recurrences. Both strategies were discussed and we decided to add Kaplan-Meier 
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curves with all patients included for comparison (Figure 17). This obviously increases the 
number of events as many patients received adjuvant treatment but also because patients with 
stage pT3b disease actually have a high risk of early recurrences that are treated with RT 
and/or ADT. In Study I we found that patients with SVI have a higher risk of recurrence than 
those without SVI, especially during the first 20 months. Therefore, many patients with stage 
pT3b with prostate cancer recurrence are probably lost when censoring treatments given the 
first 2 years after surgery.  
 
 
 
There are large differences in outcome of the RT graphs when stratifying according to 
surgical margin status depending on how many years we choose to exclude (Figure 18). A 
possible explanation is that patients with extensively positive surgical margins and pT3 stage 
disease are often candidates for early postoperative adjuvant RT. Therefore, RT as an 
indicator of progression, especially during the first 2 years after surgery, should be interpreted 
with caution. Obviously, patients with both SVI and positive surgical margins have the 
highest risk of receiving postoperative treatment and also the highest risk of dying of the 
disease. This is not surprising as margin positivity itself is known to be an adverse prognostic 
factor (163). If those who received treatment within 2 years after surgery are not excluded, it 
becomes apparent that a large proportion of patients with pT3a or pT3b cancer and positive 
Figure 17. Event-free survival with exclusion of events up to 0, 1 and 2 years after radical 
prostatectomy. 
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surgical margins receive postoperative RT. The reason for this may be that surgical margin 
status plays an important role for the decision on salvage RT or immediate adjuvant RT. 
Furthermore, we did not consider lymph node status in the analyses. Lymph node metastases 
are certainly associated with a poorer clinical outcome. However, it is unlikely that adjusting 
for lymph node status would affect the results significantly since lymph node metastases are 
uncommon among RP patients nowadays (164). 
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A 
B 
 
Figure 18. Kaplan–Meier estimates of event-free survival, by endpoint, between patients with staging category 
pT3a and pT3b tumors stratified according to surgical margin status and exclusion of patients who received 
treatment (A) 0 and (B) 2 years post-operatively. Year of diagnosis from 2008-2012.  
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Prostate cancer is often slowly growing and the 6-year disease specific survival was as high 
as 94% for men with SVI. Improved survival for these patients is probably partly a result of 
improved treatment options. ADT remains the basis in treatment of advanced prostate cancer, 
however, docetaxel improve survival for these patients and has now been available in over a 
decade (165). The last years have offered additional medical treatment as the new second-
generation anti-androgens have been introduced to the market. Abiraterone and docetaxel are 
now approved for treatment of hormone-sensitive prostate cancer, which may further improve 
survival for patients with advanced prostate cancer. In addition, the RT strategies 
continuously improve.  
Clinical nomograms are commonly used for prediction of pathology prior to surgery. These 
nomograms usually include s-PSA, biopsy GS and clinical stage and are a basis for treatment 
planning. In addition, other preoperative biopsy findings such as linear extent and percentage 
of positive biopsy cores have been suggested as predictors of SVI, however, results are 
conflicting (89, 91, 101, 102). In our study we found that men with pT3b disease had 
significantly higher tumor burden in the preoperative biopsies compared to men with pT3a 
tumors. Our results indicate that the pre-treatment prediction of SVI may improve if total 
length of cancer involvement of cores and the number of positive biopsies is included in 
clinical nomograms. However, the interquartile ranges were very broad and the lower 
quartiles had little tumor burden on biopsies. Therefore, it is doubtful that these data may be 
of clinical utility. Also, it is likely that improved radiology, with MRI as standard for these 
patients, add more to the preoperative diagnosis of SVI.  
4.3.3 Limitations of registry data 
In this study we evaluated the incidence and prognosis of a certain pathological feature based 
on information from a registry. A limitation of this study design is that no central review 
using contemporary definitions and grading was done. According to The ISUP consensus 
conference on Handling and Staging of Radical Prostatectomy Specimens in 2009, SVI 
should be defined as cancer invading the muscular wall of the extraprostatic part of the 
seminal vesicles (63). Previously, invasion of tumor cells in the surrounding adipose tissue 
was sufficient to fulfill the diagnostic criteria of SVI (62). Today, this appearance would 
rather be staged as pT3a. We had no available information on how SVI was defined in cases 
reported as pT3b tumors. This may have influenced the incidence and prognosis reported in 
this study. Furthermore, the Gleason grading system has changed during the last decade with 
a gradual shift towards higher Gleason grading, particularly after the ISUP 2005 revision (47, 
48). Of all patients with pT3b disease in this study, 7.5% had a GS of 2-6. This is not in line 
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with contemporary RP series in which SVI is an exceedingly rare finding in GS 6 tumors. 
Recently, 2502 patients with GS 6 at RP were analyzed for EPE and SVI (166). After review 
according to contemporary evaluation SVI was not found in any of the GS 6 patients and EPE 
was extremely rare, found in only seven (0.28%) patients. Although these limitations are 
important to consider, registries are a valuable source of information, which enable analysis 
of large datasets. This is especially important when analyzing unusual pathological features 
such as SVI, since clinical cohorts larger than 100 cases would be rare.  
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4.4 STUDY IV: CONVENTIONAL DIAGNOSTIC PROSTATE BIOPSIES MAY BE 
AN UNRELIABLE SOURCE FOR PERSONALIZED MEDICINE 
4.4.1 Main findings 
In Study IV the aim was to analyze the genomic heterogeneity of multifocal prostate cancer 
and to evaluate how well the preoperative biopsies represent the different tumor foci. CNVs, 
structural rearrangements and point mutations were evaluated in 11 cases of multifocal 
prostate cancer and corresponding preoperative systematic needle biopsies. In total, 22 
biopsies, 25 FFPE and 22 fresh frozen samples from 11 RP specimens were analyzed. Due to 
low quality of some of the samples we were not able to draw conclusions on somatic origin 
of 12 prostatectomy samples and seven biopsy samples. Based on the genomic profile of each 
sample they were annotated “Cancer 1, 2, 3” etc., which refers to the somatically defined 
tumor and not a spatial tumor focus.  
The three tumor foci evaluated in Case 3 all shared a mutation in the CCND1 gene. This was 
the only case in which we found a shared mutation between tumor foci. In Case 4 there were 
no similarity in somatic profile between the fresh frozen sample and the FFPE sample from 
the same tumor focus. This is an indication of a high degree of intratumoral heterogeneity.  
In Case 7 and 11 every sample had high purity and were profiled. In Case 7 we found a 
distinct separated CNV pattern between the two evaluated tumor foci, indicating that the 
tumors were somatically independent (Figure 19). The biopsies only carried information from 
one of the tumor foci, which was located in the right PZ of the prostate. In Case 11 we 
analyzed two spatially distinct tumor foci, one located in the PZ and the other in the TZ. The 
two biopsies shared a clonal SPOP hotspot mutation with the tumor samples from the tumor 
in the PZ (Figure 20). The other tumor samples lacked this mutation and the majority of 
CNVs detected in the PZ tumor. Both biopsies represented the PZ tumor, referred to as 
Cancer 2.  
In summary, 22 somatically independent cancers were detected in 24 tumor foci from 11 
patients. Of these, only 10 were represented in the diagnostic biopsies (Figure 21). In eight 
patients, at least one tumor focus was identified in the biopsies. In only one case the biopsy 
cores represented two tumor foci, however, in this case a third cancer with a different somatic 
profile was also identified. Of the mutations and structural variants detected in fresh frozen or 
FFPE prostatectomy material, only an average of 19% (range 0-44) and 55% (range 0-100), 
respectively, were found in the preoperative biopsies where a common somatic origin could 
be established. 
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4.4.2 Somatic heterogeneity  
In line with previously published studies (115, 134), our results indicate a high degree of 
genomic intratumoral heterogeneity. In a recent study, which evaluated 89 tumor foci in 41 
men, it was reported that in 76% of cases none of the foci shared any mutations (131). In our 
study we rarely found any shared aberrations between foci. We identified driver mutations 
that are important in the pathogenesis of prostate cancer. Mutations in SPOP, PTEN, 
ZMYM3, PIK3CA, TP53 and FOXA1 frequently occur in prostate cancer and we found at 
least one of them in all but one patient. Driver mutations were never shared between foci, but 
in four patients a driver mutation was shared between biopsy and RP samples. In one case we 
found mutation in PIK3CA, which is frequently mutated in other solid tumors (167) and has 
been reported as a predictive biomarker for AKT inhibitor (168). However, this mutation was 
neither found in the biopsy, nor in the other tumor focus. In concordance, Boutros et al 
analyzed a prostate with nine spatially separated foci and found that only two foci had 
mutations in PIK3CA (115). This reflects the risk of missing a potential treatment target when 
analyzing only parts of the prostate. In a study by VanderWeele et al 10 patients with 
treatment naïve, non-metastatic prostate cancer were examined and 70 spatially distinct 
regions of the index tumors were analyzed (162). They examined alterations in pathways 
associated with response in targeted treatment and found that fewer than 25% of mutations 
were present in all regions of the index tumor. These studies, and the current, are not only 
evidence of pronounced intratumoral heterogeneity, but also shows how difficult 
representative tumor sampling is. 
4.4.3 Biopsy representation and clinical implications 
The GS of diagnostic biopsies is the foundation of the treatment planning process for patients 
with localized prostate cancer. Both the urologist and the pathologist have important roles in 
the diagnostic process. From the urologist’s point of view, it is important that the needle 
biopsies actually sample the clinically most important tumor (the tumor with highest grade), 
while the pathologist has the task of grading the tumor correctly according to current 
recommendations. But tumors with identical grades may behave differently clinically, which 
is explained by genetics. Two pathologically identical regions may have significant different 
somatic profiles. For example, pronounced inter- and intratumoral genomic heterogeneity has 
been shown to occur in clinically localized GS 7 tumors (115).  
Although Gleason grading today is the most important tissue evaluation in prostate cancer, 
genomic profiling of tumors will be increasingly important in clinical practice. Studies have 
been carried out to evaluate the effect of neoadjuvant treatment prior to RP, but the clinical 
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outcome for the patients has not been improved (169). Possibly, genomic profiling of tumor 
tissue will distinguish patients who may benefit from such treatment. As core biopsy is the 
tool used at initial assessment, it is important to have a comprehension on how well the 
biopsy findings correspond to the RP findings. In this study we found that evaluation of a few 
needle biopsies does not provide a representative picture of somatically separated tumors. 
However, this is the first study that compared biopsies with RP specimens and therefore more 
studies are needed in this field.  
4.4.4 Limitations 
There are a few limitations of this study. In some of the samples there was low tumor purity, 
which made it hard to draw conclusions on somatic origin. This may be explained by the 
infiltrating growth pattern often seen in prostate cancer. In comparison to other solid tumors 
where pure tumor tissue often can be harvested, sampling of prostate cancer is usually more 
challenging. Moreover, not more than three biopsy cores were analyzed and only cores with 
more than 2 mm cancer were included. Not including all positive biopsies may have 
hampered the representation of somatically different tumors. However, an advantage of this 
approach is that the study design is similar to the clinical practice, where only a limited 
number of biopsies can be analyzed. 
In the study we analyzed biopsies that were sampled systematically. Studies have shown that 
MRI-targeted biopsies detect more clinically significant cancers (27, 28). Therefore, the 
biopsies may have been more representative of the tumors if they were targeted. However, it 
has been shown that even within an index focus there may be somatically different clones 
(134). This was also confirmed in Study II of this thesis, where we found a high degree of 
variation in CNVs between small areas within a single tumor focus. Therefore, it is not 
certain that targeted biopsies towards the index tumor would result in a better mapping of 
somatically separated tumor clones.  
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5 CONCLUSIONS 
In Study I we demonstrated that patients with SVI of prostate cancer have a poorer clinical 
outcome compared to patients without SVI. However, the prognosis for men with SVI is not 
uniformly poor. It seems that the prognosis is worse for those with tumor invasion of the 
seminal vesicles mucosa than for those where SVI is restricted to the muscular wall and 
connective tissue. Men with SVI without mucosal invasion seem to have a similar outcome as 
those with no SVI. We found that invasion of the seminal vesicle mucosa was only seen 
together with invasion of the muscular wall. This is helpful information for the pathologists 
when reading the slides. Quantitative measures of SVI (area, diameter, uni- versus bilateral 
involvement) and GS of the SVI component are not useful predictors of recurrence and do 
not need to be reported by the pathologist.  
The IDC-P component in the prostate cancer of Study II was somatically very similar to the 
lymph node metastases of this case, indicating that IDC-P may have metastatic potential. 
IDC-P is known to be an adverse pathological feature associated with poor clinical outcome. 
The current study is the first to report a somatic profile of IDC-P areas within a prostate 
cancer and correlate it with the genomics of metastases. Bulk sampling of the primary tumor 
was insufficient for establishing its relationship with the metastases. The clone that had 
seeded the metastases was not found until several distinct tumor areas of the main tumor were 
microdissected and analyzed. This reflects the pronounced tumor heterogeneity of prostate 
cancer, which is important to consider in studies analyzing the origin and metastatic pattern 
of prostate cancer. The results of this study also emphasize the importance of reporting IDC-P 
when found either associated with invasive cancer or in isolation. 
In Study III we found that SVI is associated with a poorer clinical outcome, defined as 
higher risk of initiation of post-operative RT and/or ADT and higher risk of death from 
prostate cancer, compared to EPE alone. Cancers with EPE or SVI have demonstrated their 
potential to spread outside of the prostate. The mechanism behind the poorer outcome for 
patients with SVI remains unknown. Patients with pT3b cancer seem to have a higher tumor 
burden in preoperative biopsies than those with pT3a. However, the cancer involvement in 
biopsies varies widely within each stage, which makes it unlikely that this finding will have 
much clinical utility.  
In Study IV we found that only some of somatically distinct tumors could be identified in 
multiple diagnostic biopsies. We also found an enormous genomic heterogeneity, not only 
between tumor foci, but also within a single focus. This has implications for tumor sampling, 
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which needs to be done thoroughly to enable identification of somatically different foci that 
may serve as a basis for treatment planning.  
We conclude that prostate cancer has a pronounced heterogeneity of morphology, molecular 
profile and outcome. Tumors of the same clinical stage may have completely different 
prognosis due to their unique tumor characteristics. A single case of prostate cancer may have 
different morphology and genomic profiles in different parts of the prostate and even within 
tumor foci. This leads to diagnostic challenges in the identification of the clinically most 
important tumor focus. As the possibilities of oncological treatment increase, it is likely that 
therapy in the future will be based on the genomics of the tumor. Therefore, it is of uttermost 
importance that the right clone is being selected for analysis. How this will be done in an 
optimized manner remains to be studied.  
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6 FUTURE PERSPECTIVES 
Histopathology is an important tool in risk stratification and management of prostate cancer, 
but personalized genomic profiling will be increasingly important in the future as our 
understanding of the molecular basis of prostate cancer deepens. This will help to provide the 
most effective treatment for each patient. Every patient has a unique tumor with a distinct 
molecular profile. There is also pronounced intratumoral diversity, with different genomic 
characteristics between primary and metastatic lesions and between tumor foci in the primary 
tumor (Figure 22). Also, index foci have been reported to be somatically heterogeneous, with 
many alterations present in subclonal populations (134). Collecting representative tumor 
samples for identification of relevant tumor clones may therefore be challenging, which 
furthermore limits the clinical use of genetic biomarkers.  
 
There are a few targeted therapies based on genomic changes that have shown promising 
results in metastatic prostate cancer. Patients who have high expression levels of AR usually 
respond well to AR targeted therapies (enzalutamide and abirateron) (170). Patients with 
germline BRCA mutations have recently been shown to have a high response rate to the 
PARP-inhibitor olaparib (20). PIK3CA mutation, which is frequently mutated in prostate 
cancer and other solid tumors (167), predicts response to AKT inhibitor (168). There are 
several ongoing clinical trials that further evaluate the effect of PARP and AKT inhibitors in 
this patient group. However, this thesis and previous studies show that potential treatment 
targets may be missed when only analyzing limited samples of the cancer.  
 
  
  
  
 
    
 
A B 
Figure 22. (A) The genomic profile of prostate tumors varies between patients and within a single patient. 
There is also a intratumoral diversity within a single tumor focus. (B) Multifocal prostate cancer with index 
focus in the transition zone and smaller foci in the peripheral zone. The somatic profile of the different tumor 
foci may differ significantly.  
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A better understanding of the pathogenesis of prostate cancer is needed to improve prognostic 
and predictive biomarkers. A large number of studies have been carried out to evaluate the 
clonality and heterogeneity of multifocal prostate cancer. A limitation of many studies is that 
a bulk of tumor tissue has been analyzed. Mutations that are present in a small subset of cells 
may therefore be diluted and missed. In order to thoroughly analyze the origin and clonality 
of prostate cancer single-cell analysis should be applied. This has been done in breast cancer 
and indicates a high level of diversity between cells in a tumor and that no two single cells are 
somatically identical (171). Analysis on a single cell level provides more information and 
increases our understanding of the tumor evolution. In addition, it can better predict response 
and resistance to treatment since a few cells may harbor mutations associated with resistance 
before treatment is initiated. Only a few authors have used single-cell DNA analysis to 
examine the somatic heterogeneity of prostate cancer (172, 173). Su et al recently studied the 
genomic heterogeneity at a single cell level in two cases of prostate cancer (173). The cells 
were collected using LCM. They demonstrated a significant genomic heterogeneity between 
cells from different parts of the prostate. In the first case they found the same TP53 driver 
mutation among all cells. But in the second case they found TP53 and a few other mutated 
oncogenes only in some of the cells. They concluded that the findings were consistent with a 
monoclonal origin of prostate cancer in the first case and a polyclonal origin in the second 
case. The report does not reveal how many cells that were collected for analysis. Using LCM 
in single cell analysis of prostate tissue is not reliable if only a single cell is microdissected 
since the sampling is often done on thin sections, often resulting in only a proportion of a cell 
being sampled.  
Single-cell analysis may also become important in the diagnostic situation. In a recently 
published study, single cell nuclei analysis from prostate core biopsies of 11 patients was 
done (172). CNVs were analyzed to examine the heterogeneity and clonal relationships 
between subpopulations. Cells were sampled through gentle washing of the biopsy core 
before formalin fixation. The biopsies that contained cancer according to the histopathology 
examination usually had cells with shared copy-number events, which was interpreted as 
evidence for clonal expansion. Such clones were typically not seen in benign tissue and the 
authors concluded that genomic analysis on single cell basis may serve as a tool for 
prediction of postoperative pathology.  
Certainly, more studies in this field are needed to increase the understanding of how prostate 
cancer evolves and how it can be interpreted to improve diagnostics and treatments. Genomic 
alterations could be the key to define patients with aggressive disease and ability to respond 
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to certain treatments. The somatic heterogeneity of prostate cancer aggravates the 
introduction of genomic profiling into clinical use. For tailoring of treatment it is of great 
importance not only to evaluate the genomic profile of prostate cancer and identify clones of 
particular aggressiveness, but also to further evaluate the heterogeneity of the tumors and 
potential sampling issues in the clinical setting. 
 
 
 
   65 
7 ACKNOWLEDGEMENTS 
I wish to express my sincere appreciation to everyone who has supported and shown interest 
in this work during the last years. In particular, I would like to thank: 
Lars Egevad, min huvudhandledare. Tack för att du introducerat mig till prostatapatologins 
spännande värld och för att du inspirerade mig till att påbörja detta forskningsprojekt! Jag är 
inte bara imponerad över din entusiasm och dina gedigna kunskaper, utan även din 
häpnadsväckande snabba mailrespons och ditt outtömliga förråd av anekdoter!  
Johan Lindberg, min bihandledare. Tack för att du tålmodigt guidat mig genom de genetiska 
projekten som inte hade varit möjliga utan dig. Tack för ditt stora engagemang och för att du 
aldrig tröttnat på att förklara igen! 
Henrik Grönberg, min bihandledare. Tack för alla goda råd och värdefulla synpunkter under 
doktorandtiden! 
Christine Sonnhag, min mentor tillika gudmor. Trots att vi inte diskuterat så mycket 
forskning under min doktorandtid så har vi ändå hunnit med mycket annat!  
Jóna Guðjónsdóttir och Gabriela Prochazka, mina stöttepelare i labbet. Tack vare er känns 
extraktioner, fryssnittningar och färgningar lätt - även för en kliniker!  
Linda Drevin och Fredrik Wiklund för all hjälp med statistiken! 
My co-authors Brett Delahunt, Hemamali Samaratunga, Pär Stattin, Peter Wiklund, 
David Robinson and Ingela Franck Lissbrant for fruitful cooperation and valuable input! 
Special thanks to Rebecka Bergström for all your excellent work in Study IV.  
Prof Glen Kristiansen and Dr Yuri Tolkach for the weeks at the pathology department at 
The University Hospital of Bonn. I really enjoyed the visit with a perfect mix of grossing, 
ESRP1-analysis and sauerkraut! 
Alla kollegor och vänner på Tema Cancer, Karolinska Universitetssjukhuset. Stort tack till 
min chef Fernanda Costa Svedman för ledig tid från kliniken så att jag fick möjlighet att 
skriva klart min avhandling. Carina Nord, min kliniska handledare, och alla andra på ”uro-
onkologen” som har lärt mig så mycket om prostatacancer ur ett kliniskt onkologiskt 
perspektiv. Gabriella Cohn Cedermark för överseende i schemaläggningen och värdefulla 
synpunkter i samband med min halvtidskontroll. Tack till ST-gruppen! Särskilt Anna L, 
Halla och Natalie (St Göran desertören) för att ni orkat lyssna när jag har våndats. Tack 
Caroline K för all pepp och Meis för ”statistik-räddningen”!  
Amanda Seipel och Daniela Swanberg, mina partners in crime både i och utanför 
prostatalabbet. Jag är så glad över att vi gav oss in i det här äventyret tillsammans! 
Fortsättning följer.. 
  66 
Tack även till alla andra vänner som stöttat under doktorandtiden! Särskilt tack till Sara och 
Cissi som varit med från början och alltid finns där! Tack till Sofia, Issa och Malin och 
resten av gänget för alla härliga äventyr mellan varven! 
Mina fina svärföräldrar, Sten Eirik och Bente, för mycket stöttning och många goda råd.  
Mina bröder, Magnus och Johan, som alltid ställer upp för lillasyster (eller typ alltid…i alla 
fall när man inte har golftid på St Andrews..). Bästa svägerskorna Jennifer och Linda som 
står ut med mina bröder. Sebastian och Filippa, fasters älsklingar som alltid sprider så 
mycket glädje och kärlek.  
Mina föräldrar, Elisabeth och Tormod, som har visat mig vilket fantastiskt verktyg kunskap 
är. Tack för att ni alltid finns där och stöttar mig i allt oavsett vad jag ger mig in i! Ni är bäst! 
Jesper, min stora kärlek och favoritperson i hela världen! Tack för att du är min alldeles egna 
hejarklack! 
 
 
 
 
 
 
   67 
8 REFERENCES 
 
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global 
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 
cancers in 185 countries. CA Cancer J Clin. 2018. 
2. Bergman O, Lotta F, Gabor H, Elizabeth J, Ljungman P, Munck-Wikland E, 
et al. Cancer i siffror 2018 Available from: 
http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/20976/2018-6-10.pdf2018 [ 
3. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, 
prevalence and mortality. Part I: international comparisons. BJU Int. 2002;90(2):162-73. 
4. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. 
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of 
african descent. Prostate Cancer. 2013;2013:560857. 
5. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. 
Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles 
County. Br J Cancer. 1991;63(6):963-6. 
6. Maringe C, Mangtani P, Rachet B, Leon DA, Coleman MP, dos Santos Silva 
I. Cancer incidence in South Asian migrants to England, 1986-2004: unraveling ethnic from 
socioeconomic differentials. Int J Cancer. 2013;132(8):1886-94. 
7. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, 
et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true 
prevalence. J Natl Cancer Inst. 2007;99(19):1484-9. 
8. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. 
High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma 
between the ages of 20-69: an autopsy study of 249 cases. In Vivo. 1994;8(3):439-43. 
9. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of 
prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol. 
2005;48(5):739-44. 
10. Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action 
and implications for chemoprevention. Nat Rev Urol. 2010;7(8):442-53. 
11. Sinha R, Park Y, Graubard BI, Leitzmann MF, Hollenbeck A, Schatzkin A, et 
al. Meat and meat-related compounds and risk of prostate cancer in a large prospective 
cohort study in the United States. Am J Epidemiol. 2009;170(9):1165-77. 
12. Ellinger S, Ellinger J, Stehle P. Tomatoes, tomato products and lycopene in 
the prevention and treatment of prostate cancer: do we have the evidence from intervention 
studies? Curr Opin Clin Nutr Metab Care. 2006;9(6):722-7. 
13. Kicinski M, Vangronsveld J, Nawrot TS. An epidemiological reappraisal of 
the familial aggregation of prostate cancer: a meta-analysis. PLoS One. 2011;6(10):e27130. 
14. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. 
Oncogene. 2004;23(38):6445-70. 
15. Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. 
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J 
Med. 2016;375(5):443-53. 
16. Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards 
SM, et al. The frequency of germ-line mutations in the breast cancer predisposition genes 
BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British 
Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res. 
2000;60(16):4513-8. 
17. Akbari MR, Wallis CJ, Toi A, Trachtenberg J, Sun P, Narod SA, et al. The 
impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br J 
Cancer. 2014;111(6):1238-40. 
  68 
18. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, 
Mahmud N, et al. BRCA2 is a moderate penetrance gene contributing to young-onset 
prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer. 
2011;105(8):1230-4. 
19. Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T, 
Castro E, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 
2012;106(10):1697-701. 
20. Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. 
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 
2015;373(18):1697-708. 
21. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, et 
al. A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate 
cancer. Nat Genet. 2014;46(10):1103-9. 
22. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders 
EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer 
susceptibility loci. Nat Genet. 2018;50(7):928-36. 
23. Varenhorst E, Berglund K, Lofman O, Pedersen K. Inter-observer variation in 
assessment of the prostate by digital rectal examination. Br J Urol. 1993;72(2):173-6. 
24. Jones D, Friend C, Dreher A, Allgar V, Macleod U. The diagnostic test 
accuracy of rectal examination for prostate cancer diagnosis in symptomatic patients: a 
systematic review. BMC Fam Pract. 2018;19(1):79. 
25. Rao AR, Motiwala HG, Karim OM. The discovery of prostate-specific 
antigen. BJU Int. 2008;101(1):5-10. 
26. Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, et al. 
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate 
cancer: recommendations from a European consensus meeting. Eur Urol. 2011;59(4):477-
94. 
27. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, 
et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer 
(PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-22. 
28. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, 
Vaarala MH, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N 
Engl J Med. 2018;378(19):1767-77. 
29. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 
2014 International Society of Urological Pathology (ISUP) Consensus Conference on 
Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a 
New Grading System. Am J Surg Pathol. 2016;40(2):244-52. 
30. Alberts AR, Bokhorst LP, Kweldam CF, Schoots IG, van der Kwast TH, van 
Leenders GJ, et al. Biopsy undergrading in men with Gleason score 6 and fatal prostate 
cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam. Int 
J Urol. 2017;24(4):281-6. 
31. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, et al. Direct 
detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 
2017;9(403). 
32. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. 
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci 
Transl Med. 2014;6(224):224ra24. 
33. Carignan A, Roussy JF, Lapointe V, Valiquette L, Sabbagh R, Pepin J. 
Increasing risk of infectious complications after transrectal ultrasound-guided prostate 
biopsies: time to reassess antimicrobial prophylaxis? Eur Urol. 2012;62(3):453-9. 
   69 
34. Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y, et 
al. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective 
population-based diagnostic study. Lancet Oncol. 2015;16(16):1667-76. 
35. Nordstrom T, Picker W, Aly M, Jaderling F, Adolfsson J, Strom P, et al. 
Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, 
the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. Eur Urol Focus. 
2017;3(6):526-8. 
36. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of 
Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100(11):2362-6. 
37. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et 
al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J 
Natl Cancer Inst. 1998;90(3):233-7. 
38. Seipel AH, Delahunt B, Samaratunga H, Egevad L. Ductal adenocarcinoma of 
the prostate: histogenesis, biology and clinicopathological features. Pathology. 
2016;48(5):398-405. 
39. Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, et 
al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to 
Prostate Cancer Risk Categories. Eur Urol. 2017;72(4):492-5. 
40. Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without 
invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol. 
2010;184(4):1328-33. 
41. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and 
c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and 
carcinoma by fluorescence in situ hybridization. Mod Pathol. 1997;10(11):1113-9. 
42. Varma M, Egevad L, Algaba F, Berney D, Bubendorf L, Camparo P, et al. 
Intraductal carcinoma of prostate reporting practice: a survey of expert European 
uropathologists. J Clin Pathol. 2016;69(10):852-7. 
43. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: 
Histologic features and clinical significance. Mod Pathol. 2006;19(12):1528-35. 
44. Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, et al. Prognostic 
value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate. 
2014;74(6):680-7. 
45. Masoomian M, Downes MR, Sweet J, Cheung C, Evans AJ, Fleshner N, et al. 
Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform 
carcinoma in a prospectively collected data set. Histopathology. 2019;74(3):474-82. 
46. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 
1966;50(3):125-8. 
47. Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 
1998-2011: a registry study of 97,168 men. BJU Int. 2015;115(2):248-55. 
48. Epstein JI, Allsbrook WC, Jr., Amin MB, Egevad LL, Committee IG. The 
2005 International Society of Urological Pathology (ISUP) Consensus Conference on 
Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29(9):1228-42. 
49. Samaratunga H, Delahunt B, Gianduzzo T, Coughlin G, Duffy D, LeFevre I, 
et al. The prognostic significance of the 2014 International Society of Urological Pathology 
(ISUP) grading system for prostate cancer. Pathology. 2015;47(6):515-9. 
50. Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, 
et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the 
Gleason Score. Eur Urol. 2016;69(3):428-35. 
51. Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin 
MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer 
eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(3):245-53. 
  70 
52. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et 
al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict 
pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 
1997;277(18):1445-51. 
53. Rider JR, Sandin F, Andren O, Wiklund P, Hugosson J, Stattin P. Long-term 
outcomes among noncuratively treated men according to prostate cancer risk category in a 
nationwide, population-based study. Eur Urol. 2013;63(1):88-96. 
54. Aus G, Robinson D, Rosell J, Sandblom G, Varenhorst E, South-East Region 
Prostate Cancer G. Survival in prostate carcinoma--outcomes from a prospective, 
population-based cohort of 8887 men with up to 15 years of follow-up: results from three 
countries in the population-based National Prostate Cancer Registry of Sweden. Cancer. 
2005;103(5):943-51. 
55. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. 
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data 
from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, 
CRUK/06/019). Eur Urol. 2015;67(6):1028-38. 
56. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-
Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With 
Castration-Resistant Prostate Cancer. J Clin Oncol. 2016;34(14):1652-9. 
57. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression 
following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-
up. Am J Surg Pathol. 1996;20(3):286-92. 
58. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Capsular 
penetration in prostate cancer. Significance for natural history and treatment. Am J Surg 
Pathol. 1990;14(3):240-7. 
59. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et 
al. Clinical and pathological significance of the level and extent of capsular invasion in 
clinical stage T1-2 prostate cancer. Hum Pathol. 1998;29(8):856-62. 
60. Danneman D, Wiklund F, Wiklund NP, Egevad L. Prognostic significance of 
histopathological features of extraprostatic extension of prostate cancer. Histopathology. 
2013;63(4):580-9. 
61. Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, et al. The 
relationship between the extent of extraprostatic extension and survival following radical 
prostatectomy. Eur Urol. 2015;67(2):342-6. 
62. Jewett HJ, Eggleston JC, Yawn DH. Radical prostatectomy in the 
management of carcinoma of the prostate: probable causes of some therapeutic failures. J 
Urol. 1972;107(6):1034-40. 
63. Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey 
PA, et al. International Society of Urological Pathology (ISUP) Consensus Conference on 
Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal 
vesicles and lymph nodes. Mod Pathol. 2011;24(1):39-47. 
64. Epstein JI, Partin AW, Potter SR, Walsh PC. Adenocarcinoma of the prostate 
invading the seminal vesicle: prognostic stratification based on pathologic parameters. 
Urology. 2000;56(2):283-8. 
65. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate 
invading the seminal vesicle: definition and relation of tumor volume, grade and margins of 
resection to prognosis. J Urol. 1993;149(5):1040-5. 
66. Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G. Prognostic 
significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale 
for seminal vesicle biopsies. Eur Urol. 1998;33(3):271-7. 
   71 
67. Villers AA, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Pathogenesis 
and biological significance of seminal vesicle invasion in prostatic adenocarcinoma. J Urol. 
1990;143(6):1183-7. 
68. Ohori M, Scardino PT, Lapin SL, Seale-Hawkins C, Link J, Wheeler TM. The 
mechanisms and prognostic significance of seminal vesicle involvement by prostate cancer. 
Am J Surg Pathol. 1993;17(12):1252-61. 
69. Samaratunga H, Samaratunga D, Perry-Keene J, Adamson M, Yaxley J, 
Delahunt B. Distal seminal vesicle invasion by prostate adenocarcinoma does not occur in 
isolation of proximal seminal vesicle invasion or lymphovascular infiltration. Pathology. 
2010;42(4):330-3. 
70. Mukamel E, deKernion JB, Hannah J, Smith RB, Skinner DG, Goodwin WE. 
The incidence and significance of seminal vesicle invasion in patients with adenocarcinoma 
of the prostate. Cancer. 1987;59(8):1535-8. 
71. Pierorazio PM, Ross AE, Schaeffer EM, Epstein JI, Han M, Walsh PC, et al. 
A contemporary analysis of outcomes of adenocarcinoma of the prostate with seminal 
vesicle invasion (pT3b) after radical prostatectomy. J Urol. 2011;185(5):1691-7. 
72. Freedland SJ, Aronson WJ, Presti JC, Jr., Amling CL, Terris MK, Trock B, et 
al. Predictors of prostate-specific antigen progression among men with seminal vesicle 
invasion at the time of radical prostatectomy. Cancer. 2004;100(8):1633-8. 
73. Salomon L, Anastasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, 
Abbou CC, et al. Seminal vesicle involvement after radical prostatectomy: predicting risk 
factors for progression. Urology. 2003;62(2):304-9. 
74. Masterson TA, Pettus JA, Middleton RG, Stephenson RA. Isolated seminal 
vesicle invasion imparts better outcomes after radical retropubic prostatectomy for 
clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and 
margin status. Urology. 2005;66(1):152-5. 
75. Secin FP, Bianco FJ, Jr., Vickers AJ, Reuter V, Wheeler T, Fearn PA, et al. 
Cancer-specific survival and predictors of prostate-specific antigen recurrence and survival 
in patients with seminal vesicle invasion after radical prostatectomy. Cancer. 
2006;106(11):2369-75. 
76. Sofer M, Savoie M, Kim SS, Civantos F, Soloway MS. Biochemical and 
pathological predictors of the recurrence of prostatic adenocarcinoma with seminal vesicle 
invasion. J Urol. 2003;169(1):153-6. 
77. Eggener SE, Roehl KA, Smith ND, Antenor JA, Han M, Catalona WJ. 
Contemporary survival results and the role of radiation therapy in patients with node 
negative seminal vesicle invasion following radical prostatectomy. J Urol. 
2005;173(4):1150-5. 
78. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, 
Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that 
predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J 
Urol. 1995;154(1):131-8. 
79. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with 
progression after radical retropubic prostatectomy. Cancer. 1993;71(11):3582-93. 
80. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic 
significance of positive surgical margins in radical prostatectomy specimens. J Urol. 
1995;154(5):1818-24. 
81. Forgues A, Rozet F, Audenet F, Ouzzane A, Sanchez-Salas R, Barret E, et al. 
Oncologic outcomes after minimally invasive radical prostatectomy in patients with 
seminal vesicle invasion (pT3b) without adjuvant therapy. World J Urol. 2014;32(2):519-
24. 
  72 
82. Tefilli MV, Gheiler EL, Tiguert R, Banerjee M, Sakr W, Grignon DJ, et al. 
Prognostic indicators in patients with seminal vesicle involvement following radical 
prostatectomy for clinically localized prostate cancer. J Urol. 1998;160(3 Pt 1):802-6. 
83. Bayne CE, Williams SB, Cooperberg MR, Gleave ME, Graefen M, Montorsi 
F, et al. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts 
and Future Perspectives. Eur Urol. 2016;69(5):775-87. 
84. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. 
Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk 
of metastases and improves survival: long-term followup of a randomized clinical trial. J 
Urol. 2009;181(3):956-62. 
85. Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. 
Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up 
of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243-50. 
86. Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, 
et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: 
long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 
2012;380(9858):2018-27. 
87. Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a 
nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. 
Cancer. 1997;79(3):528-37. 
88. Narayan P, Gajendran V, Taylor SP, Tewari A, Presti JC, Jr., Leidich R, et al. 
The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum 
prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic 
diagnosis in prostate cancer. Urology. 1995;46(2):205-12. 
89. Bostwick DG, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP, et al. 
Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol. 
1996;155(4):1361-7. 
90. Guzzo TJ, Vira M, Wang Y, Tomaszewski J, D'Amico A, Wein AJ, et al. 
Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle 
involvement in patients with prostate cancer. J Urol. 2006;175(2):518-21; discussion 21-2. 
91. Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, et al. 
Percent of prostate needle biopsy cores with cancer is significant independent predictor of 
prostate specific antigen recurrence following radical prostatectomy: results from SEARCH 
database. J Urol. 2003;169(6):2136-41. 
92. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A 
preoperative nomogram for disease recurrence following radical prostatectomy for prostate 
cancer. J Natl Cancer Inst. 1998;90(10):766-71. 
93. Lee YI, Lee HM, Jo JK, Lee S, Hong SK, Byun SS, et al. Association 
between Seminal Vesicle Invasion and Prostate Cancer Detection Location after Transrectal 
Systemic Biopsy among Men Who Underwent Radical Prostatectomy. PLoS One. 
2016;11(2):e0148690. 
94. Vallancien G, Prapotnich D, Veillon B, Brisset JM, Andre-Bougaran J. 
Seminal vesicle biopsies in the preoperative staging of prostatic cancer. Eur Urol. 
1991;19(3):196-200. 
95. Allepuz Losa CA, Sanz Velez JI, Gil Sanz MJ, Mas LP, Rioja Sanz LA. 
Seminal vesicle biopsy in prostate cancer staging. J Urol. 1995;154(4):1407-11. 
96. Linzer DG, Stock RG, Stone NN, Ratnow R, Ianuzzi C, Unger P. Seminal 
vesicle biopsy: accuracy and implications for staging of prostate cancer. Urology. 
1996;48(5):757-61. 
97. Sung MT, Eble JN, Cheng L. Invasion of fat justifies assignment of stage 
pT3a in prostatic adenocarcinoma. Pathology. 2006;38(4):309-11. 
   73 
98. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The 
use of prostate specific antigen, clinical stage and Gleason score to predict pathological 
stage in men with localized prostate cancer. J Urol. 1993;150(1):110-4. 
99. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. 
Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new 
millennium. Urology. 2001;58(6):843-8. 
100. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, et 
al. Investigating the clinical utility of the percent of positive prostate biopsies in predicting 
PSA outcome following local therapy for patients with clinically localized prostate cancer. 
Prostate Cancer Prostatic Dis. 2000;3(4):259-64. 
101. Gallina A, Chun FK, Briganti A, Shariat SF, Montorsi F, Salonia A, et al. 
Development and split-sample validation of a nomogram predicting the probability of 
seminal vesicle invasion at radical prostatectomy. Eur Urol. 2007;52(1):98-105. 
102. Koh H, Kattan MW, Scardino PT, Suyama K, Maru N, Slawin K, et al. A 
nomogram to predict seminal vesicle invasion by the extent and location of cancer in 
systematic biopsy results. J Urol. 2003;170(4 Pt 1):1203-8. 
103. Soylu FN, Peng Y, Jiang Y, Wang S, Schmid-Tannwald C, Sethi I, et al. 
Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal 
MR imaging. Radiology. 2013;267(3):797-806. 
104. Grivas N, Hinnen K, de Jong J, Heemsbergen W, Moonen L, Witteveen T, et 
al. Seminal vesicle invasion on multi-parametric magnetic resonance imaging: Correlation 
with histopathology. Eur J Radiol. 2018;98:107-12. 
105. de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of 
Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-
analysis. Eur Urol. 2016;70(2):233-45. 
106. Baumgartner EM, Porter KK, Nix JW, Rais-Bahrami S, Gordetsky JB. 
Detection of extraprostatic disease and seminal vesicle invasion in patients undergoing 
magnetic resonance imaging-targeted prostate biopsies. Transl Androl Urol. 2018;7(Suppl 
4):S392-S6. 
107. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et 
al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 
2012;487(7406):239-43. 
108. Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, 
et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential 
therapeutic targets and disease heterogeneity. Eur Urol. 2013;63(5):920-6. 
109. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et 
al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. 
Science. 2005;310(5748):644-8. 
110. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, 
et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of 
prostate cancer. Cancer Res. 2006;66(17):8337-41. 
111. St John J, Powell K, Conley-Lacomb MK, Chinni SR. TMPRSS2-ERG 
Fusion Gene Expression in Prostate Tumor Cells and Its Clinical and Biological 
Significance in Prostate Cancer Progression. J Cancer Sci Ther. 2012;4(4):94-101. 
112. Perner S, Svensson MA, Hossain RR, Day JR, Groskopf J, Slaughter RC, et 
al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology. 
2010;75(4):762-7. 
113. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, et al. The 
TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort 
study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1497-509. 
  74 
114. Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, et al. Complex 
patterns of ETS gene alteration arise during cancer development in the human prostate. 
Oncogene. 2008;27(14):1993-2003. 
115. Boutros PC, Fraser M, Harding NJ, de Borja R, Trudel D, Lalonde E, et al. 
Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 
2015;47(7):736-45. 
116. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, et al. 
Substantial interindividual and limited intraindividual genomic diversity among tumors 
from men with metastatic prostate cancer. Nat Med. 2016;22(4):369-78. 
117. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor 
suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res. 1998;4(3):811-
5. 
118. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. 
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate 
cancer tissues. Cancer Res. 1998;58(2):204-9. 
119. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et 
al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated 
with poor clinical outcome. Br J Cancer. 2007;97(5):678-85. 
120. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum 
M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA 
recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 
2012;181(2):401-12. 
121. Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, et al. PTEN 
loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN 
FISH in a large retrospective prostatectomy cohort. Oncotarget. 2017;8(39):65566-76. 
122. Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, 
et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15(4):222-
34. 
123. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat 
JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in 
prostate cancer. Nat Genet. 2012;44(6):685-9. 
124. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable 
suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15(15):4792-8. 
125. Hu CD, Choo R, Huang J. Neuroendocrine differentiation in prostate cancer: 
a mechanism of radioresistance and treatment failure. Front Oncol. 2015;5:90. 
126. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and 
therapeutic implications. Hum Pathol. 2010;41(6):781-93. 
127. Kobayashi M, Ishida H, Shindo T, Niwa S, Kino M, Kawamura K, et al. 
Molecular analysis of multifocal prostate cancer by comparative genomic hybridization. 
Prostate. 2008;68(16):1715-24. 
128. Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, et al. Exome 
sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur 
Urol. 2013;63(2):347-53. 
129. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, et al. 
Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by 
fluorescence in situ hybridization. Cancer Res. 1995;55(22):5408-14. 
130. Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, et al. 
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: 
molecular evidence for an independent group of diseases. Cancer Res. 2007;67(17):7991-5. 
131. Lovf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, et al. 
Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Eur 
Urol. 2018. 
   75 
132. Boyd LK, Mao X, Xue L, Lin D, Chaplin T, Kudahetti SC, et al. High-
resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal 
prostate cancer. Genes Chromosomes Cancer. 2012;51(6):579-89. 
133. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, et 
al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple 
independent clonal expansions in neoplastic and morphologically normal prostate tissue. 
Nat Genet. 2015;47(4):367-72. 
134. Wei L, Wang J, Lampert E, Schlanger S, DePriest AD, Hu Q, et al. 
Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate 
Cancer Impacts Molecular Classifications and Genomic Prognosticators. Eur Urol. 
2017;71(2):183-92. 
135. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number 
analysis indicates monoclonal origin of lethal metastatic prostate cancer.  Nat Med. 15. 
United States2009. p. 559-65. 
136. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, et al. 
Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad 
Sci U S A. 2011;108(29):12054-9. 
137. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, et 
al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123(11):4918-22. 
138. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, 
Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. 
Nature. 2015;520(7547):353-7. 
139. Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, et al. DNA 
methylation alterations exhibit intraindividual stability and interindividual heterogeneity in 
prostate cancer metastases. Sci Transl Med. 2013;5(169):169ra10. 
140. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate 
Cancer. N Engl J Med. 2016;375(15):1415-24. 
141. Bjorklund J, Folkvaljon Y, Cole A, Carlsson S, Robinson D, Loeb S, et al. 
Postoperative mortality 90 days after robot-assisted laparoscopic prostatectomy and 
retropubic radical prostatectomy: a nationwide population-based study. BJU Int. 
2016;118(2):302-6. 
142. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, et al. 
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-
assisted radical prostatectomy. Eur Urol. 2012;62(3):382-404. 
143. Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. 
Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for 
prostate cancer in an era of improving radiological staging techniques. World J Urol. 
2018;36(1):15-20. 
144. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, et al. 
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized 
Prostate Cancer. J Clin Oncol. 2017;35(17):1884-90. 
145. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, et al. 
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced 
prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 
2011;12(5):451-9. 
146. van Oort IM, Bruins HM, Kiemeney LA, Knipscheer BC, Witjes JA, 
Hulsbergen-van de Kaa CA. The length of positive surgical margins correlates with 
biochemical recurrence after radical prostatectomy. Histopathology. 2010;56(4):464-71. 
147. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et 
al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy 
  76 
in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, 
platform randomised controlled trial. Lancet. 2016;387(10024):1163-77. 
148. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, 
et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N 
Engl J Med. 2017;377(4):352-60. 
149. Chism DD, De Silva D, Whang YE. Mechanisms of acquired resistance to 
androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev 
Anticancer Ther. 2014;14(11):1369-78. 
150. Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to 
systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 
2017;57:16-27. 
151. Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, et al. The 
mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol. 
2013;63(4):702-8. 
152. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein 
SR, et al. Laser capture microdissection. Science. 1996;274(5289):998-1001. 
153. Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, et 
al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, 
structural rearrangements and clonal hematopoiesis. Genome Med. 2018;10(1):85. 
154. Stef van Buuren KG-O. mice: Multivariate Imputation by Chained Equations 
in R2011; 45(3). Available from: http://www.jstatsoft.org/v45/i03/. 
155. Potter SR, Mangold LA, Shue MJ, Taylor DC, Lecksell KL, Epstein JI, et al. 
Molecular and immunohistochemical staging of men with seminal vesicle invasion and 
negative pelvic lymph nodes at radical prostatectomy. Cancer. 2000;89(12):2577-86. 
156. Trudel D, Downes MR, Sykes J, Kron KJ, Trachtenberg J, van der Kwast TH. 
Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture 
after prostatectomy in a contemporary cohort. Eur J Cancer. 2014;50(9):1610-6. 
157. Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, et 
al. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk 
prostate cancer patients treated by radiotherapy. Eur J Cancer. 2012;48(9):1318-25. 
158. Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal 
JE, et al. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade 
dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer 
progression. Prostate. 2000;44(4):265-70. 
159. Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, et al. 
Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from 
high-grade prostatic intraepithelial neoplasia. Mod Pathol. 2013;26(4):587-603. 
160. Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, et al. 
Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral 
resection and enucleation specimens: recommendations from the International 
Collaboration on Cancer Reporting (ICCR). Pathology. 2019;51(1):11-20. 
161. Iczkowski KA, Egevad L, Ma J, Harding-Jackson N, Algaba F, Billis A, et al. 
Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic 
pathologists. Ann Diagn Pathol. 2014;18(6):333-42. 
162. VanderWeele DJ, Finney R, Katayama K, Gillard M, Paner G, Imoto S, et al. 
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive 
Biomarkers of Targeted Therapy. Eur Urol Focus. 2018. 
163. Pettus JA, Weight CJ, Thompson CJ, Middleton RG, Stephenson RA. 
Biochemical failure in men following radical retropubic prostatectomy: impact of surgical 
margin status and location. J Urol. 2004;172(1):129-32. 
164. Pierorazio PM, Gorin MA, Ross AE, Feng Z, Trock BJ, Schaeffer EM, et al. 
Pathological and oncologic outcomes for men with positive lymph nodes at radical 
   77 
prostatectomy: The Johns Hopkins Hospital 30-year experience. Prostate. 
2013;73(15):1673-80. 
165. Fossa SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, et al. 
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent 
prostate cancer: a randomized phase II study. Eur Urol. 2007;52(6):1691-8. 
166. Anderson BB, Oberlin DT, Razmaria AA, Choy B, Zagaja GP, Shalhav AL, 
et al. Extraprostatic Extension Is Extremely Rare for Contemporary Gleason Score 6 
Prostate Cancer. Eur Urol. 2017;72(3):455-60. 
167. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High 
frequency of mutations of the PIK3CA gene in human cancers. Science. 
2004;304(5670):554. 
168. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, et al. Biomarkers of 
response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res. 2012;18(20):5816-
28. 
169. Pignot G, Maillet D, Gross E, Barthelemy P, Beauval JB, Constans-
Schlurmann F, et al. Systemic treatments for high-risk localized prostate cancer. Nat Rev 
Urol. 2018;15(8):498-510. 
170. Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP. Treating 
Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of 
Available Therapies. J Urol. 2015;194(6):1537-47. 
171. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal 
evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 
2014;512(7513):155-60. 
172. Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, et al. 
Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. Cancer Res. 
2018;78(2):348-58. 
173. Su F, Zhang W, Zhang D, Zhang Y, Pang C, Huang Y, et al. Spatial 
Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-
nucleus Sequencing. Eur Urol. 2018;74(5):551-9. 
 
